

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 12:45:05 +0000
To: NIAID OD AM
Subject: FW: Question

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Siegel, Marc (b) (6)
Sent: Wednesday, January 22, 2020 7:03 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Re: Question

Just quoted you on Fox and Friends.

We want to know if you might be interested in coming to NYU to give Grand Rounds sometime over the next several weeks - on this coronavirus and vaccine candidate.

Grand Rounds are Wednesday mornings at 8 AM

It would be a great honor and pleasure to have you here.

We would of course cover all expenses and your fee.

Hope you will consider.

Marc

Sent from my iPhone

On Jan 22, 2020, at 5:52 AM, Fauci, Anthony (NIH/NIAID) [E] <(b) (6)> wrote:

[EXTERNAL]

Marc:

You certainly can quote me.

Best regards,

Tony

From: Siegel, Marc [REDACTED] (b) (6)
Sent: Tuesday, January 21, 2020 10:30 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: Re: Question

thanks Tony!

hope I can quote you!

From: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Sent: Tuesday, January 21, 2020 10:00:21 PM
To: Siegel, Marc
Subject: RE: Question

[EXTERNAL]

Marc:

Thanks for the note. We are already working on a vaccine for the 2019 n-CoV. We have the sequence of the virus and are employing an mRNA vaccine platform in collaboration with the Moderna Company. We hope to have the candidate in Phase 1 trials within 3 months. You might remember that we actually developed a DNA vaccine for SARS (another coronavirus pathogen) several years ago and brought it through Phase 1 trials showing safety and immunogenicity. We never developed it further since the SARS outbreak was completely stopped by good public health measures. Bottom line is that there is a good chance that over time, we will develop a vaccine for this virus.

Best regards,

Tony

-----Original Message-----

From: Siegel, Marc [REDACTED] (b) (6) >
Sent: Tuesday, January 21, 2020 4:41 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Question

Tony

Any chance of a vaccine for this coronavirus?

I believe they were testing one in dogs.

Marc

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 14:20:33 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD: Meeting with Richard Hackett (CEPI)
Attachments: Re: Coming to DC Wednesday

I'm flying in for the meeting at the World Bank Thursday morning and was hoping you and Hilary and Barney and John might have time to meet Wednesday afternoon to discuss the Moderna project. I'm also trying to organize a pre-meeting at the Bank on Wednesday, so late afternoon would probably be better. Alternatively, late Thursday afternoon might work as well. I hope we can find a time that works

--

Best regards,
Richard

RICHARD HATCHETT
CEO



From: Marston, Hilary (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 20:41:44 +0000
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: Re: Coming to DC Wednesday

And Paula Bryant

On Feb 17, 2020, at 3:32 PM, Marston, Hilary (NIH/NIAID) [E] [REDACTED] (b) (6) wrote:

Hey Kim,

Thanks for helping with this. Meeting would probably need 60 mins. Participants from NIAID: ASF

Hugh (optional)

John Mascola

Barney Graham

Julie Ledgerwood

Karin Bok

Emily Erbeling

Cristina Cassetti

John Beigel

Hilary Marston

Andrea Lerner

Bob (optional)

Emily and Andrea might be tied up with AFM workshop. John Beigel would be important to have there. I'll work with Richard and Barney on an agenda.

Please let me know if you need anything else!

Begin forwarded message:

From: "Conrad, Patricia (NIH/NIAID) [E]" [REDACTED] (b) (6)>

Date: February 17, 2020 at 10:53:39 AM EST

To: "Marston, Hilary (NIH/NIAID) [E]" [REDACTED] (b) (6)>

Cc: "Barasch, Kimberly (NIH/NIAID) [C]" [REDACTED] (b) (6), "Folkers, Greg (NIH/NIAID) [E]" [REDACTED] (b) (6), "Fauci, Anthony (NIH/NIAID) [E]" [REDACTED] (b) (6)>

Subject: Re: Coming to DC Wednesday

Kim

Pls work with Hilary to schedule this after meeting with ASF about best timing and how long this meeting will need to be. Thx.

Sent from my iPhone

On Feb 17, 2020, at 10:35 AM, Marston, Hilary (NIH/NIAID) [E] [REDACTED] (b) (6) wrote:

From: Richard Hatchett [REDACTED] (b) (6) >
Date: Monday, February 17, 2020 at 10:10 AM
To: Anthony Fauci [REDACTED] (b) (6) >
Cc: Hilary Marston [REDACTED] (b) (6) >
Subject: Coming to DC Wednesday

Dear Tony,

I hope all is well – I know you've been busy.

I'm flying in for the meeting at the World Bank Thursday morning and was hoping you and Hilary and Barney and John might have time to meet Wednesday afternoon to discuss the Moderna project. I'm also trying to organize a pre-meeting at the Bank on Wednesday, so late afternoon would probably be better. Alternatively, late Thursday afternoon might work as well. I hope we can find a time that works

--

Best regards,
Richard

RICHARD HATCHETT
CEO

[<image001.png>](#)

[REDACTED] (b) (6)

[REDACTED] (b) (6)

Visiting address: Gibbs building, 215 Euston Rd, Bloomsbury, London NW1 2BE, UK
Postal address: P.O. BOX 123, Torshov, 0412 Oslo, Norway

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 14:20:33 +0000
To: Fauci, Anthony (NIH/NIAID) [E];Mascola, John (NIH/VRC) [E];Graham, Barney (NIH/VRC) [E];Ledgerwood, Julie (NIH/NIAID) [E];Bok, Karin (NIH/VRC) [E];Erbelding, Emily (NIH/NIAID) [E];Cassetti, Cristina (NIH/NIAID) [E];Beigel, John (NIH) [E];Bryant, Paula (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID) [E];Eisinger, Robert (NIH/NIAID) [E];Auchincloss, Hugh (NIH/NIAID) [E];Handley, Gray (NIH/NIAID) [E];Steven T. Smith;Auchincloss, Hugh (NIH/NIAID) [E];Auchincloss, Hugh (NIH/NIAID) [E]
Cc: Suhana, Tina (NIH/VRC) [E];Austin, Sarah (NIH/NIAID) [E];Young, Monique (NIH/VRC) [E];Taylor, Stephanie (NIH/NIAID) [E];Treadwell-Hyde, Roshawn (NIH/NIAID) [C];Robinson, Whitney (NIH/NIAID) [C];Guarin, Radd (NIH/NIAID) [C]
Subject: Meeting with Richard Hatchett (CEPI)
Attachments: Re: Coming to DC Wednesday

*****New Dial-In*****

Wed, Feb 19, 2020 5:00 PM - 6:00 PM (EST)

Please join my meeting from your computer, tablet or smartphone.

(b) (6)

You can also dial in using your phone.

(For supported devices, tap a one-touch number below to join instantly.)

United States (Toll Free): 1 866 899 4679

- One-touch: (b) (6)

United States: +1 (646) 749-3117

- One-touch: (b) (6)

United Kingdom (Toll Free): 0 800 389 5276

- One-touch: (b) (6)

United Kingdom: +44 330 221 0097

- One-touch: (b) (6)

Access Code: (b) (6)

I'm flying in for the meeting at the World Bank Thursday morning and was hoping you and Hilary and Barney and John might have time to meet Wednesday afternoon to discuss the Moderna project. I'm also trying to organize a pre-meeting at the Bank on Wednesday, so late afternoon would probably be better. Alternatively, late Thursday afternoon might work as well. I hope we can find a time that works

--

Best regards,
Richard

RICHARD HATCHETT
CEO



From: Marston, Hilary (NIH/NIAID) [E]
Sent: Mon, 17 Feb 2020 20:41:44 +0000
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: Re: Coming to DC Wednesday

And Paula Bryant

On Feb 17, 2020, at 3:32 PM, Marston, Hilary (NIH/NIAID) [E] (b) (6) wrote:

Hey Kim,

Thanks for helping with this. Meeting would probably need 60 mins. Participants from NIAID: ASF

Hugh (optional)

John Mascola

Barney Graham

Julie Ledgerwood

Karin Bok

Emily Erbeling

Cristina Cassetti

John Beigel

Hilary Marston

Andrea Lerner

Bob (optional)

Emily and Andrea might be tied up with AFM workshop. John Beigel would be important to have there. I'll work with Richard and Barney on an agenda.

Please let me know if you need anything else!

Begin forwarded message:

From: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)>

Date: February 17, 2020 at 10:53:39 AM EST

To: "Marston, Hilary (NIH/NIAID) [E]" (b) (6)>

Cc: "Barasch, Kimberly (NIH/NIAID) [C]" (b) (6), "Folkers, Greg (NIH/NIAID) [E]" (b) (6), "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>

Subject: Re: Coming to DC Wednesday

Kim

Pls work with Hilary to schedule this after meeting with ASF about best timing and how long this meeting will need to be. Thx.

Sent from my iPhone

On Feb 17, 2020, at 10:35 AM, Marston, Hilary (NIH/NIAID) [E] [REDACTED] (b) (6) wrote:

From: Richard Hatchett [REDACTED] (b) (6) >
Date: Monday, February 17, 2020 at 10:10 AM
To: Anthony Fauci [REDACTED] (b) (6) >
Cc: Hilary Marston [REDACTED] (b) (6) >
Subject: Coming to DC Wednesday

Dear Tony,

I hope all is well – I know you’ve been busy.

I’m flying in for the meeting at the World Bank Thursday morning and was hoping you and Hilary and Barney and John might have time to meet Wednesday afternoon to discuss the Moderna project. I’m also trying to organize a pre-meeting at the Bank on Wednesday, so late afternoon would probably be better. Alternatively, late Thursday afternoon might work as well. I hope we can find a time that works

--

Best regards,
Richard

RICHARD HATCHETT
CEO

[<image001.png>](#)

[REDACTED] (b) (6)

[REDACTED] (b) (6)

Visiting address: Gibbs building, 215 Euston Rd, Bloomsbury, London NW1 2BE, UK
Postal address: P.O. BOX 123, Torshov, 0412 Oslo, Norway

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Jan 2020 23:34:05 +0000
To: Fauci, Anthony (NIH/NIAID) [E];Mascola, John (NIH/VRC) [E];Graham, Barney (NIH/VRC) [E];Suhana, Tina (NIH/VRC) [E];Austin, Sarah (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C];Young, Monique (NIH/VRC) [E]
Subject: Meeting with Stephane Bancel, Moderna
Attachments: RE: Monday in DC

From: Conrad, Patricia (NIH/NIAID) [E]
Sent: Sun, 26 Jan 2020 23:32:12 +0000
To: Stephane Bancel
Cc: Mascola, John (NIH/VRC) [E];Graham, Barney (NIH/VRC) [E];Nadege Ripley;Fauci, Anthony (NIH/NIAID) [E]
Subject: RE: Monday in DC

Great – see you then. Thank you.

From: Stephane Bancel [REDACTED] (b) (6)
Sent: Saturday, January 25, 2020 9:00 PM
To: Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6)>
Cc: Mascola, John (NIH/VRC) [E] [REDACTED] (b) (6); Graham, Barney (NIH/VRC) [E] <[REDACTED] (b) (6)>; Nadege Ripley [REDACTED] (b) (6)
Subject: Re: Monday in DC

Perfect. I will be there at 8 am.

Thank you very much

Stephane

Get [Outlook for iOS](#)

From: Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6)>
Sent: Saturday, January 25, 2020 9:15:04 PM
To: Stephane Bancel [REDACTED] (b) (6)>
Cc: Mascola, John (NIH/VRC) [E] [REDACTED] (b) (6); Graham, Barney (NIH/VRC) [E] [REDACTED] (b) (6)
Subject: Re: Monday in DC

Dr Fauci can be available for a meeting in his office at NIH on Monday Jan 27 at 8:00 am - 8:30 am ET.

We are located in Building 31A at 31 Center Drive. Please allow sufficient time to go through the NIH Security/gateway center. A valid photo I.D is required. Our office is on the 7th floor A-wing elevators - Room 7A03.

If you have any problems on the day of the visit please call us at [REDACTED] (b) (6) and please send us your cell as well.

At your convenience, please confirm to all cc'd on this email that this meeting time will work for your schedule. Thank you and we look forward to seeing you on Monday.

Best,

Patricia L. Conrad
Special Assistant to the Director

Sent from my iPhone

On Jan 25, 2020, at 10:44 AM, Stephane Bancel <[REDACTED] (b) (6)> wrote:

John.

[REDACTED] (b) (4)

So lots to talk about. But on it.

[REDACTED] (b) (4)

Let me know a time Monday am and I will be at VRC. Cheers

Stephane

Get [Outlook for iOS](#)

From: Mascola, John (NIH/VRC) [E] [REDACTED] (b) (6)>
Sent: Saturday, January 25, 2020 4:37:01 PM
To: Stephane Bancel [REDACTED] (b) (6); Graham, Barney (NIH/VRC) [E]
[REDACTED] (b) (6)>
Cc: xsb-Tony Fauci [REDACTED] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: RE: Monday in DC

Stephane,

I can arrange to meet Monday morning. Have copied Patty from Tony's office to see if he can accommodate.

It would be useful to review timelines and plans. [REDACTED] (b) (4)

Thanks,
John

From: Stephane Bancel [REDACTED] (b) (6) >
Sent: Saturday, January 25, 2020 10:29 AM
To: Graham, Barney (NIH/VRC) [E] [REDACTED] (b) (6) >
Cc: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >; Mascola, John (NIH/VRC) [E] [REDACTED] (b) (6) >
Subject: Re: Monday in DC

Ok thank you.

John maybe we can meet quickly?

Thanks. Stephane

Get [Outlook for iOS](#)

From: Graham, Barney (NIH/VRC) [E] [REDACTED] (b) (6)
Sent: Saturday, January 25, 2020 3:39:52 PM
To: Stephane Bancel [REDACTED] (b) (6) >
Cc: xsb-Tony Fauci [REDACTED] (b) (6) >; Mascola, John (NIH/VRC) [E] [REDACTED] (b) (6) >
Subject: Re: Monday in DC

Hi Stephane,

Thanks for your note. We are progressing well and making protein this weekend. Your team is coordinating with us and DMID and the system seems to be functioning smoothly with good communication. CEPI seems to be plugged in and thinking about this in the right way. I am encouraged.

I will be leaving for Europe early afternoon on Monday for a Pneumonia symposium and the schedule is very crowded before that. I won't have much time that day to meet.

Barney

Sent from my iPhone

On Jan 25, 2020, at 9:02 AM, Stephane Bancel <[REDACTED]> wrote:

Gentlemen

Just to let you know I have shortened my trip in Europe and am flying back to the us tomorrow. Sunday.

I am going straight to DC so we can have a better opportunity to work on our plans

I would appreciate if we could meet Monday am

Stephane.

Get [Outlook for iOS](#)

 **Please consider the environment before printing this email**

Confidentiality notice and disclaimer: The information in this message and any attachments is intended for the exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, of any such information by persons or entities other than the intended addressee(s) is prohibited. If you have received this message in error and are not the intended addressee, please notify the sender immediately and delete this message and any attachments from your system without reading or disclosing them. If you are not the intended addressee, be advised that any use of the information in this message and any attachment is prohibited and may be unlawful, and you must not copy this message or attachment or disclose the contents to any other person.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 5 Mar 2020 20:53:35 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Interview for an Italian Newsletter - corona
Attachments: RE: Interview with Dr. Anthony Fauci, RE: Need to Reschedule: Interview with Dr. Anthony Fauci, RE: Interview with Italian Newsletter

My numbers are:

Office: 1-514 253-2332

Mobile: [REDACTED] (b) (6)

Vittorio Giordano

Editor in Chief

www.cittadino.ca

Office: 514 253-2332

Mobile [REDACTED] (b) (6)

Cell. italiano: [REDACTED] (b) (6)

Skype: vittorio__giordano

Twitter: @vittoriog82

ca.linkedin.com/pub/vittorio-giordano/47/5a/416

Facebook: facebook.com/vittorio.giordano

Il Cittadino Canadese su Rai Italia (05-01-2014):

<https://www.youtube.com/watch?v=839P42S6zqo>

From: Conrad, Patricia (NIH/NIAID) [E]
Sent: Fri, 14 Feb 2020 18:00:31 +0000
To: Cittadino Canadese
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: Interview with Dr. Anthony Fauci

Dr Fauci can be available to speak with you on March 6th at 3:00 pm ET. Please call us at (b) (6) and please send us your cell number as back up.

Thank you,

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892

(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Cittadino Canadese <journal@cittadino.ca>
Sent: Friday, February 14, 2020 12:55 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: RE: Interview with Dr. Anthony Fauci

Hello Patricia, that's an amazing news! THANK YOU! 😊

I can interview Dr. Fauci the 4,5 or 6 march, anytime is better for him.

Let me know, please.

Regards.

Vittorio Giordano
Editor in Chief
www.cittadino.ca
Office: 514 253-2332

Mobile: (b) (6)
Cell. italiano: (b) (6)
Skype: vittorio__giordano
Twitter: @vittoriog82
ca.linkedin.com/pub/vittorio-giordano/47/5a/416
Facebook: facebook.com/vittorio.giordano
Il Cittadino Canadese su Rai Italia (05-01-2014):
<https://www.youtube.com/watch?v=839P42S6zqo>

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: February 14, 2020 12:45 PM
To: Cittadino Canadese
Subject: RE: Interview with Dr. Anthony Fauci

Good afternoon:

Dr Fauci would be happy to speak with you but his schedule for the next week or so is quite full and fluid due to the nature of the current outbreak. Would it be possible to do the interview when his schedule is not so erratic – perhaps in early March?

Let me know if that works and I can send you some dates.

Best,

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Cittadino Canadese <journal@cittadino.ca>
Sent: Wednesday, February 12, 2020 1:16 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>

Cc: Barasch, Kimberly (NIH/NIAID) [C] (b) (6)>; Doepel, Laurie (NIH/NIAID) [E]
(b) (6)>

Subject: Interview with Dr. Anthony Fauci

Hello Miss Patricia Conrad, how are you?

Miss Natalie Wulderk of the NIAF (National Italian American Foundation) gave me your email.

My name is Vittorio Giordano and I am the editor in chief of IL CITTADINO CANADESE (www.cittadino.ca), an Italian weekly published in Montreal (Canada) since 1941.

It's been 1 year now that I work also for IL MESSAGGERO DI SANT'ANTONIO (<https://messaggerosantantonio.it/>), a monthly magazine published in Padova (Italy) since 1968.

The publisher asked me to do an interview with Dr. Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), a formidable Italian-American excellence, considering also the historical period that we are living now, with this coronavirus that is spreading all over the world.

I would like to know if it's possible to do an interview, over the phone (20 minutes max), in the next few days, with the Dr. Anthony S. Fauci.

Thank you for your assistance in this matter.

Your help is greatly appreciated.

Best regards.

Vittorio Giordano

Editor in Chief

www.cittadino.ca

Office: 514 253-2332

Mobile: (b) (6)

Cell. italiano: (b) (6)

Skype: vittorio__giordano

Twitter: @vittoriog82

ca.linkedin.com/pub/vittorio-giordano/47/5a/416

Facebook: facebook.com/vittorio.giordano

Il Cittadino Canadese su Rai Italia (05-01-2014):

<https://www.youtube.com/watch?v=839P42S6zqo>

From: Barasch, Kimberly (NIH/NIAID) [C]
Sent: Thu, 5 Mar 2020 20:53:25 +0000
To: Cittadino Canadese
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Need to Reschedule: Interview with Dr. Anthony Fauci

Thank you, much appreciated.

Please call our office at (b) (6) on March 10th at 12:00pm ET. We will reconfirm with you the day prior.

Thank you,
Kim

Kim Barasch [C]
Office of the Director
National Institute of Allergy & Infectious Diseases
(b) (6)

From: Cittadino Canadese <journal@cittadino.ca>
Sent: Thursday, March 5, 2020 3:38 PM
To: Barasch, Kimberly (NIH/NIAID) [C] (b) (6)>
Subject: RE: Need to Reschedule: Interview with Dr. Anthony Fauci

Hello Kim, I completely understand.

Tuesday, March 10th at 12:00pm ET is perfect.

Thank you.

Vittorio Giordano
Editor in Chief
www.cittadino.ca
Office: 514 253-2332
Mobile: (b) (6)
Cell. italiano: (b) (6)
Skype: vittorio__giordano
Twitter: @vittoriog82
ca.linkedin.com/pub/vittorio-giordano/47/5a/416
Facebook: facebook.com/vittorio.giordano
Il Cittadino Canadese su Rai Italia (05-01-2014):
<https://www.youtube.com/watch?v=839P42S6zqo>

From: Barasch, Kimberly (NIH/NIAID) [C] (b) (6)
Sent: March 5, 2020 3:25 PM

To: Cittadino Canadese
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: Need to Reschedule: Interview with Dr. Anthony Fauci
Importance: High

Dear Vittorio,

Apologies, Dr. Fauci has been called into a high-level meeting tomorrow, March 6th that will conflict with your scheduled interview. Can we please reschedule for next week - either Monday, March 9th at 1:00pm ET or Tuesday, March 10th at 12:00pm ET?

Thank you,
Kim

Kim Barasch [C]
Office of the Director
National Institute of Allergy & Infectious Diseases

(b) (6)

From: Conrad, Patricia (NIH/NIAID) [E]
Sent: Friday, February 14, 2020 1:01 PM
To: Cittadino Canadese <journal@cittadino.ca>
Cc: Barasch, Kimberly (NIH/NIAID) [C] (b) (6)
Subject: RE: Interview with Dr. Anthony Fauci

Dr Fauci can be available to speak with you on March 6th at 3:00 pm ET. Please call us at (b) (6) and please send us your cell number as back up.

Thank you,

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892

(b) (6)

301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Cittadino Canadese <journal@cittadino.ca>
Sent: Friday, February 14, 2020 12:55 PM
To: Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: RE: Interview with Dr. Anthony Fauci

Hello Patricia, that's an amazing news! THANK YOU! 😊

I can interview Dr. Fauci the 4,5 or 6 march, anytime is better for him.

Let me know, please.

Regards.

Vittorio Giordano
Editor in Chief
www.cittadino.ca
Office: 514 253-2332
Mobile: [REDACTED] (b) (6)
Cell. italiano: [REDACTED] (b) (6)
Skype: vittorio__giordano
Twitter: @vittoriog82
ca.linkedin.com/pub/vittorio-giordano/47/5a/416
[Facebook: facebook.com/vittorio.giordano](https://facebook.com/vittorio.giordano)
Il Cittadino Canadese su Rai Italia (05-01-2014):
<https://www.youtube.com/watch?v=839P42S6zqo>

From: Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6)]
Sent: February 14, 2020 12:45 PM
To: Cittadino Canadese
Subject: RE: Interview with Dr. Anthony Fauci

Good afternoon:

Dr Fauci would be happy to speak with you but his schedule for the next week or so is quite full and fluid due to the nature of the current outbreak. Would it be possible to do the interview when his schedule is not so erratic – perhaps in early March?

Let me know if that works and I can send you some dates.

Best,

Patricia L. Conrad

Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Cittadino Canadese <journal@cittadino.ca>
Sent: Wednesday, February 12, 2020 1:16 PM
To: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Cc: Barasch, Kimberly (NIH/NIAID) [C] <(b) (6)>; Doepel, Laurie (NIH/NIAID) [E]
(b) (6)
Subject: Interview with Dr. Anthony Fauci

Hello Miss Patricia Conrad, how are you?

Miss Natalie Wulderk of the NIAF (National Italian American Foundation) gave me your email.

My name is Vittorio Giordano and I am the editor in chief of IL CITTADINO CANADESE (www.cittadino.ca), an Italian weekly published in Montreal (Canada) since 1941.

It's been 1 year now that I work also for IL MESSAGGERO DI SANT'ANTONIO (<https://messaggerosantantonio.it/>), a monthly magazine published in Padova (Italy) since 1968.

The publisher asked me to do an interview with Dr. Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), a formidable Italian-American excellence, considering also the historical period that we are living now, with this coronavirus that is spreading all over the world.

I would like to know if it's possible to do an interview, over the phone (20 minutes max), in the next few days, with the Dr. Anthony S. Fauci.

Thank you for your assistance in this matter.

Your help is greatly appreciated.

Best regards.

Vittorio Giordano
Editor in Chief

www.cittadino.ca

Office: 514 253-2332

Mobile: [REDACTED] (b) (6)

Cell. italiano: [REDACTED] (b) (6)

Skype: vittorio__giordano

Twitter: @vittoriog82

ca.linkedin.com/pub/vittorio-giordano/47/5a/416

Facebook: facebook.com/vittorio.giordano

Il Cittadino Canadese su Rai Italia (05-01-2014):

<https://www.youtube.com/watch?v=839P42S6zqo>

From: Deatrick, Elizabeth (NIH/NIAID) [C]
Sent: Thu, 5 Mar 2020 21:38:07 +0000
To: Barasch, Kimberly (NIH/NIAID) [C]; NIAID COGCORE
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Interview with Italian Newsletter
Attachments: Re: Interview request: novel coronavirus (week of Mar. 1)

Hi Kim,

This interview was just cleared (please review attached email).

Best,
Elizabeth

From: Barasch, Kimberly (NIH/NIAID) [C] [REDACTED] (b) (6)>
Sent: Thursday, March 5, 2020 3:21 PM
To: NIAID COGCORE <COGCORE@mail.nih.gov>
Cc: Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Interview with Italian Newsletter

Good afternoon,

We had scheduled an interview with an Italian Newsletter for tomorrow, March 6, prior to the OVP needing to clear media requests. Please see the attached email. Can we send this for clearance? Will push this interview for Monday or Tuesday of next week.

Thanks,
Kim

Kim Barasch [C]
Office of the Director
National Institute of Allergy & Infectious Diseases
[REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 14:54:02 +0000
To: Stephane Bancel
Cc: Routh, Jennifer (NIH/NIAID) [E];Billet, Courtney (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Mascola, John (NIH/VRC) [E]
Subject: RE: CEPI. NIH. Moderna.

Stephane:

Please connect your press person with my mine. Her name is Jennifer Routh and I have copied her on this e-mail.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stephane Bancel <(b) (6)>
Sent: Wednesday, January 22, 2020 12:55 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Richard Hatchett (b) (6)
Subject: CEPI. NIH. Moderna.

Dear Tony,

I just spoke to Richard at CEPI. We are both in Europe at davos. We are finalizing, hopefully over the next 24-48h a grant from CEPI to moderna to help with funding of GMP material.

We are thinking of doing a PR potentially Friday am Europe time

Would you be open to do a joint PR. NIH. CEPI and moderna sharing our partnership ? Antigen design. mRNA platform. Funding and pandemic response.

Let us know

Cheers

Stephane

Get [Outlook for iOS](#)

 **Please consider the environment before printing this email**

Confidentiality notice and disclaimer: The information in this message and any attachments is intended for the exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, of any such information by persons or entities other than the intended addressee(s) is prohibited. If you have received this message in error and are not the intended addressee, please notify the sender immediately and delete this message and any attachments from your system without reading or disclosing them. If you are not the intended addressee, be advised that any use of the information in this message and any attachment is prohibited and may be unlawful, and you must not copy this message or attachment or disclose the contents to any other person.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Jan 2020 00:51:30 +0000
To: Richard Hatchett
Subject: RE: Moderna agreement

Richard:

Terrific! Look forward to working with you.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Richard Hatchett (b) (6)>
Sent: Wednesday, January 22, 2020 7:15 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Moderna agreement

Dear Tony,

Just a quick head's up that our agreement with Moderna to support GMP manufacturing has been signed. This will be announced at 9a ET tomorrow morning - we're looking forward to working with you and Barney and VRC on this project -

Best regards,
Richard

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 03:31:59 +0000
To: jin yan
Subject: RE: your remarks: adapt previous monoclonal antibodies, which help the immune system attack foreign substances

We have already begun the development of a vaccine using the mRNA platform in collaboration with the Moderna Company. We expect to begin a phase 1 clinical trial for safety within the next 3 months.

From: jin yan [REDACTED] (b) (6) >
Sent: Thursday, January 23, 2020 11:57 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: your remarks: adapt previous monoclonal antibodies, which help the immune system attack foreign substances

Dear Dr Anthony S Fauci,

this is Jin Yan, the Washington bureau chief with Caijing Magazine, the leading business and finance journal with international recognition. (<http://english.caijing.com.cn/mediapraise/index.html>)
i read your comments with Time Magazine, how is the experimental vaccine going? have you contacted Wuhan for more information?

many thanks

looking forward to hearing from you.

best regards

--

jin yan

Washington Bureau Chief

CAIJING Magazine

Mob: [REDACTED] (b) (6)

Tel : 202-525-2117

Email : [REDACTED] (b) (6)

yanjin@caijing.com.cn

3133 Connecticut Ave, NW, #110A

Washington DC, 20008

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 23:13:09 +0000
To: Siegel, Marc
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Question

Marc:

Thanks for the note. Am stuck for a while in DC with the coronavirus situation. I will let you know about any future possibility of my coming up there.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Siegel, Marc (b) (6) >
Sent: Wednesday, January 22, 2020 7:03 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Re: Question

Just quoted you on Fox and Friends.

We want to know if you might be interested in coming to NYU to give Grand Rounds sometime over the next several weeks - on this coronavirus and vaccine candidate.

Grand Rounds are Wednesday mornings at 8 AM

It would be a great honor and pleasure to have you here.

We would of course cover all expenses and your fee.

Hope you will consider.

Marc

Sent from my iPhone

On Jan 22, 2020, at 5:52 AM, Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) > wrote:

[EXTERNAL]

Marc:

You certainly can quote me.

Best regards,

Tony

From: Siegel, Marc [REDACTED] (b) (6) >
Sent: Tuesday, January 21, 2020 10:30 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: Re: Question

thanks Tony!

hope I can quote you!

From: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Sent: Tuesday, January 21, 2020 10:00:21 PM
To: Siegel, Marc
Subject: RE: Question

[EXTERNAL]

Marc:

Thanks for the note. We are already working on a vaccine for the 2019 n-CoV. We have the sequence of the virus and are employing an mRNA vaccine platform in collaboration with the Moderna Company. We hope to have the candidate in Phase 1 trials within 3 months. You might remember that we actually developed a DNA vaccine for SARS (another coronavirus pathogen) several years ago and brought it through Phase 1 trials showing safety and immunogenicity. We never developed it further since the SARS outbreak was completely stopped by good public health measures. Bottom line is that there is a good chance that over time, we will develop a vaccine for this virus.

Best regards,

Tony

-----Original Message-----

From: Siegel, Marc [REDACTED] (b) (6)
Sent: Tuesday, January 21, 2020 4:41 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Question

Tony

Any chance of a vaccine for this coronavirus?

I believe they were testing one in dogs.

Marc

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Jan 2020 02:00:26 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Called the office- not urgent

I will call tomorrow to address these issues. Thanks.

-----Original Message-----

From: Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Sent: Saturday, January 25, 2020 7:35 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: Called the office- not urgent

A few things to discuss for Monday

- 1 Moderna meeting
- 2 added ASPR brief with Azar
- 3 Marc Siegel media request for hannity

Call whenever,,,,,can be tomorrow. Not urgent. Have a good night

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 11:16:51 +0000
To: Graham, Barney (NIH/VRC) [E]; Mascola, John (NIH/VRC) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: CoV. Antibody?

Could one of you please respond to Stephane. Thanks.

From: Stephane Bancel <[REDACTED] (b) (6)>
Sent: Wednesday, January 22, 2020 2:29 AM
To: Graham, Barney (NIH/VRC) [E] [REDACTED] (b) (6)>; Mascola, John (NIH/VRC) [E]
[REDACTED] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: CoV. Antibody?

Dear Tony, John and Barney

Sorry for another email. I was wondering. [REDACTED] (b) (4)

[REDACTED] (b) (4)

Cheers. Stephane

Get [Outlook for iOS](#)

 **Please consider the environment before printing this email**

Confidentiality notice and disclaimer: The information in this message and any attachments is intended for the exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, of any such information by persons or entities other than the intended addressee(s) is prohibited. If you have received this message in error and are not the intended addressee, please notify the sender immediately and delete this message and any attachments from your system without reading or disclosing them. If you are not the intended addressee, be advised that any use of the information in this message and any attachment is prohibited and may be unlawful, and you must not copy this message or attachment or disclose the contents to any other person.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 13:00:39 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Time-Sensitive Media Request from Scientific American: Chinese Coronavirus

See my edits in **red**. You can forward these to her.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Sent: Tuesday, January 21, 2020 4:50 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: Time-Sensitive Media Request from Scientific American: Chinese Coronavirus

Do you want to edit this?

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it

from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Deatrick, Elizabeth (NIH/NIAID) [C] <[REDACTED] (b) (6)>
Sent: Tuesday, January 21, 2020 4:47 PM
To: Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: FW: Time-Sensitive Media Request from Scientific American: Chinese Coronavirus

Hi Patty,

See below—Tanya Lewis, at Scientific American, has asked if ASF can review the transcript of their convo. Let me know if there's anything I can do to help.

Best,
Elizabeth

From: Tanya Lewis <tlewis@sciam.com>
Sent: Tuesday, January 21, 2020 4:43 PM
To: Deatrick, Elizabeth (NIH/NIAID) [C] [REDACTED] (b) (6)>
Subject: Re: Time-Sensitive Media Request from Scientific American: Chinese Coronavirus

Hi Elizabeth,

I just spoke with Dr. Fauci—thanks for arranging the call on short notice! I don't usually do this, but I had some problems with my recording software, so I wondered if I could run the transcript of my interview by Dr. Fauci to make sure I copied everything correctly. Can you ask Dr. Fauci to review it for accuracy only? (We may edit the conversation slightly for length and clarity, but it will be pretty close to this):

Do we know how the U.S. patient contracted the virus? The earliest cases appeared to be people who had been to a seafood market in Wuhan, but there have since been documented cases of human-to-human transmission.

He [the patient] was not in any market where there may have been an animal reservoir, and he does not recall coming into contact with someone who was ill. That's not surprising— **often people contract respiratory infections without knowing the definite exposure source**. But he was in Wuhan.

Do you suspect the virus is transmitted via a respiratory route?

A respiratory infection is almost certainly transmitted through droplets. Respiratory spread is a very good guess. We have **definitively proven that the virus entered through the respiratory tract**, but it is highly likely. When you have symptoms of fever, cough, infiltrates in the lung, and respiratory [symptoms]... historically, respiratory is the route.

How similar or different is the virus from other Coronaviruses such as SARS and MERS?

First of all, it's a Coronavirus, the same family as SARS. It has some of the same molecular homology as SARS. It's closer to SARS than it is to MERS. But it isn't overwhelmingly close.

Do we know the mortality rate of the new virus?

It's a moving target. It's a rough estimate. If you look at the number of cases, it's around 300. There have been six deaths so far. That's about 2 percent mortality. But we have not identified all the cases. We're only seeing the ones who are hospitalized. If there are asymptomatic infections, the mortality rate would be much less. Among symptomatic people, the mortality rate is around 2 percent. It was 10 percent with SARS, and 30-35 percent with MERS. It may be less virulent than those two, or it may evolve. It's too early to know.

Aren't the symptoms of this viral infection similar to many other types of respiratory infection? How can you tell them apart?

It's a syndromic and epidemiological association. If somebody comes into an emergency room in Washington with a respiratory illness and they haven't been to China, they probably have the flu or some other virus. But if they came from Wuhan, [it's likely to be the new Coronavirus]. The symptoms are very common to a number of viruses, though, so it's [based on] epidemiology.

How are the patients with this virus being treated?

It's mostly symptomatic treatment. There are experimental antivirals that have been used *in vitro* and *in vivo*. If [the patients] need antibiotics **for complicating bacterial infections**, you give them antibiotics. If they need to be put on a respirator, they're put on a respirator. Most [patients] in China are doing well. But a proportion of them are very ill, and are on respirators.

How long will it be before we have a vaccine for this virus?

We've already started to develop a vaccine. We got the [genetic] sequence from the Chinese. We're partnering with a company called Moderna to develop a messenger RNA-based platform for a vaccine. We will likely have a candidate in **early phase 1 trials for safety in** about three months. That doesn't mean we will have **a vaccine ready for use in three months; even in an emergency, that would take a year or more.**

Is the most likely source of this virus an animal market in Wuhan?

It almost certainly came from an animal. Almost certainly.

How common are Coronaviruses, and how often do they jump from animals to humans?

Coronaviruses represent 10-30 percent of common colds. Over the last 18 years, we've had three coronaviruses from animal reservoirs: SARS, MERS, and now this. There could be several intermediary hosts, but at least with SARS and MERS, the primary host is thought to be a bat. [We don't know what the primary host is for this virus yet.]

Thanks very much,

Tanya

--

Tanya Lewis
Associate Editor, Health and Medicine
Scientific American
New York, NY
Office #: 212-451-8419
Cell #: (b) (6)

From: Administrator <tlewis@sciam.com>

Date: Tuesday, January 21, 2020 at 1:25 PM

To: "Deatrck, Elizabeth (NIH/NIAID) [C]" <(b) (6)>

Subject: Re: Time-Sensitive Media Request from Scientific American: Chinese Coronavirus

Hi Elizabeth,

Thanks for getting back to me. I don't have a hard deadline, but as this is a quickly evolving topic, I'd like to file something fairly soon. I am aware of the CDC telecom this afternoon, and plan on listening in. But I'm still interested in speaking with Dr. Fauci if he's available.

Best,
Tanya

--

Tanya Lewis
Associate Editor, Health and Medicine
Scientific American
New York, NY
Office #: 212-451-8419
Cell #: (b) (6)

From: "Deatrck, Elizabeth (NIH/NIAID) [C]" <(b) (6)>

Date: Tuesday, January 21, 2020 at 1:01 PM

To: Administrator <tlewis@sciam.com>

Subject: RE: Time-Sensitive Media Request from Scientific American: Chinese Coronavirus

Hi Tanya,

Thank you for reaching out to NIAID. I'll be checking with Dr. Fauci to see if he's available for an interview tomorrow morning, or late this afternoon. Do you have a hard deadline tomorrow you're working to meet?

Also, in case you're unaware, the CDC is having a telebriefing on this topic later this afternoon—it may answer some of your questions (see attachment for details). If you're still interested in a call afterwards, we'd be happy to work on that for you.

Best,
Elizabeth

From: Tanya Lewis <tlewis@sciam.com>

Sent: Tuesday, January 21, 2020 12:41 PM

To: NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>

Cc: Deatrck, Elizabeth (NIH/NIAID) [C] <(b) (6)>; Oplinger, Anne (NIH/NIAID) [E] <(b) (6)>

Subject: Time-Sensitive Media Request from Scientific American: Chinese Coronavirus

Dear NIAID press officers,

I'm a news editor at Scientific American, and I'm reporting a story on the ongoing outbreak of a new coronavirus from China. I'm writing to request an interview with Dr. Fauci, or someone else in your agency who is an expert on this topic, or coronaviruses in general. I'm hoping to file my story no later than noon ET tomorrow. Let me know if you can set something up for this afternoon (anytime except 2-3 ET), or first thing tomorrow morning. Thanks!

Best regards,

Tanya

--

Tanya Lewis
Associate Editor, Health and Medicine
Scientific American
New York, NY
Office #: 212-451-8419
Cell #: (b) (6)

DISCLAIMER: This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage mechanism. Springer Nature America, Inc. does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of Springer Nature America, Inc. or one of their agents. Please note that neither Springer Nature America, Inc. or any of its agents accept any responsibility for viruses that may be contained in this e-mail or its attachments and it is your responsibility to scan the e-mail and attachments (if any).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 14:21:23 +0000
To: Collins, Francis (NIH/OD) [E]
Subject: RE: Any coronavirus update?

Francis:

You can use any of the information in my 01/21/2020 e-mail. There are close to 500 cases (440 at last count) and 9 deaths. Mortality remains at around 2% for people who are recognized with sx's. No evidence at present regarding asymptomatic infections. In addition to the ORD and ATL airports plus JFK, LAX and SFO, DHS will work out funneling people coming from China to USA through these 5 airports. Also, CDC has elevated their Travel Alert to Level 2, which means enhanced precaution. Level 1 is business as usual and Level 3 is only essential travel.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Wednesday, January 22, 2020 8:22 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Burklow, John (NIH/OD) [E] (b) (6); Myles, Renate (NIH/OD) [E] (b) (6); Tabak, Lawrence (NIH/OD) [E] (b) (6) >
Subject: Any coronavirus update?

Hi Tony,

I'm doing a Swiss Radio interview at 4 pm in Davos (10 am EST). It's supposed to be wide-ranging about many issues in biomedical research, but I'd be surprised if they don't bring up the coronavirus situation.

Stephane Bancel sent me a heads up (just forwarded to you) that Moderna was announcing their collaboration with NIH on an RNA based vaccine development, as you told me yesterday. Just so I'm clear, is there anything in your message from 1/21 11:13 AM that I should NOT mention? And is there anything new in the last 24 hours other than screening at Chicago and Atlanta airports?

Thanks for all your help on this!

Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Jan 2020 03:32:43 +0000
To: Bryant, Paula (NIH/NIAID) [E]
Cc: Erbelding, Emily (NIH/NIAID) [E];Cassetti, Cristina (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Greg Folkers (b) (6);Marston, Hilary (NIH/NIAID) [E]
Subject: CEPI

Paula:

I just had a call with Richard Hatchett and Melanie Saville from CEPI about the Moderna partnership. At the end of the call, he asked if NIAID would be willing to extend preclinical services in-kind support to CEPI's n-CoV activities. I told him that I would be supportive and that I would connect with you.

If you have any concerns, please let me know.

Best,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 03:09:30 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: URGENT GPMB: Message on behalf of the Co-Chairs: Proposed Board teleconference THIS MONDAY

OK. Have Steve sit in for us and de-brief us. You do the Moderna meeting.

From: Marston, Hilary (NIH/NIAID) [E] (b) (6)>
Sent: Sunday, January 26, 2020 10:08 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Re: URGENT GPMB: Message on behalf of the Co-Chairs: Proposed Board teleconference THIS MONDAY

It looks like it overlaps with the Moderna meeting. I will participate in whichever you tell me to (of course), but Steve Smith can listen into GPMB (and has been following/meeting with secretariat etc).

From: Anthony Fauci (b) (6)>
Date: Sunday, January 26, 2020 at 10:01 PM
To: Hilary Marston <(b) (6)>
Subject: FW: URGENT GPMB: Message on behalf of the Co-Chairs: Proposed Board teleconference THIS MONDAY

Can you listen in on this? It overlaps with an AMA call.

From: GPMB Secretariat <gpmbssecretariat@who.int>
Sent: Friday, January 24, 2020 9:39 AM
To: As Sy Elhadj (b) (6); Brundtland Gro Harlem (b) (6) Dzau Victor <(b) (6)>; Chris.Elias (b) (6)>; Farrar Jeremy <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Fore Henrietta (b) (6) Gao Fu (b) (6)>; Gashumba Diane (b) (6)>; Kaag Sigrid (b) (6)>; Ilona Kickbusch (b) (6)>; Skvortsova Veronika (b) (6)>; Suzuki Yasuhiro (b) (6) Vega Morales Jeanette (b) (6)>; Vega Morales Jeanette (b) (6); VijayRaghavan Krishnaswamy (b) (6)
Cc: MAHJOUR, Jaouad (b) (6); MINHAS, Raman <(b) (6)>; Toomas Palu (b) (6); Pate Muhamed (b) (6)>; RYAN, Michael J. (b) (6)>; SCHWARTLANDER, Bernhard F (b) (6)>; Alex Harris (b) (6)>; Alveberg, Benedikte Louise (b) (6)>; Chiaki NOGUCHI (b) (6)>; Esveld Marja (b) (6)>; Esveld Marja (b) (6) Esveld Marja (b) (6)>; Gonggrijp Mette (b) (6)>; Julie.HALL (b) (6)>; Kanarek Morgan (b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6)>; Oleg Sonin <(b) (6)>; Omar Abdi (b) (6)>; Amelie RIOUX (b) (6)>; Tore Godal <(b) (6)>

GABEDAVA, Tsira (b) (6); ROSS, Alex (b) (6); Banks Lynn
(b) (6); Block Bruce (b) (6); Conrad Jane
(b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Del Sol Dinia
(b) (6); Diao Fay (b) (6); Elena Kirsanova
(b) (6); Gahungu Zacharie (b) (6); Harikumar M K
(b) (6); Harikumar M K (b) (6); Kabagire Christine
(b) (6); KITA Yosuke (b) (6); Miller de Vega Teresa
(b) (6); MURIUKI, Hilda Wairimu (b) (6); Muzenda Sindiso
(b) (6); Sarah Belmir (b) (6); YU Bai (b) (6)

Subject: URGENT GPMB: Message on behalf of the Co-Chairs: Proposed Board teleconference THIS MONDAY

Importance: High

Dear Board members,

As many of you, we are concerned about the Novel 2019-Coronavirus outbreak. We believe the Board has a role to play in supporting the response and encouraging countries to step up their preparedness activities, as well as to support WHO in their efforts.

As co-chairs of the GPMB we therefore suggest to hold a **teleconference** of the Board to discuss the outbreak.

An outcome of the call could be a GPMB statement supporting the response and highlighting crucial preparedness activities that should be undertaken, or other suggestions to be discussed.

We would suggest to hold the teleconference call on **Monday 27 January at 1400-1500 Geneva time**. This is the only time next week the Co-Chairs are available.

Attached is information for a telephone bridge for the call. We would appreciate it if you could please confirm your participation.

We will share with you shortly a more detailed agenda.

We look forward to hearing from you on this and thank you for your continued engagement.

Kinds regards,

Gro and As

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 23:42:59 +0000
To: Routh, Jennifer (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]
Subject: RE: For review (due to HHS for White House by 8:30 tonight): press conference talking points
Attachments: Talking Points for NIAID Director Dr. Fauci - press conference - 01-28-2020.docx

Here it is with my minor edits. Thanks!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Routh, Jennifer (NIH/NIAID) [E] (b) (6) >
Sent: Monday, January 27, 2020 6:14 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Marston, Hilary (NIH/NIAID) [E] (b) (6) >
Subject: For review (due to HHS for White House by 8:30 tonight): press conference talking points

Dr. Fauci –

You will be making brief remarks at the HHS press conference tomorrow. HHS has requested your talking points by 8:30 tonight. (They are really just a placeholder for the White House to have something and so they are not surprised by any news). I have attached proposed points and pasted them below.

Please let me know if you have edits. I will send the final version to HHS tonight.

Thanks,
Jen

Talking Points for NIAID Director Anthony S. Fauci, M.D.

HHS Press Conference on Coordinated Public Health Response to 2019 Novel Coronavirus

- NIAID has a dual mandate to not only pursue a robust research portfolio in the areas of microbiology, infectious diseases and immunology, but also to quickly launch a research response to newly emerging and reemerging infectious diseases.
- When MERS, another coronavirus, emerged in 2012, NIAID researchers mobilized rapidly to characterize the virus and develop diagnostics, treatments and vaccines.
- NIAID's research response to this novel coronavirus will build on our experience with SARS and MERS. This will include continuing basic or fundamental research to better understand the virus as well as developing and testing rapid, point-of-care diagnostics, vaccines, and treatments, including broad-spectrum antivirals and antibody therapies.
- NIAID is collaborating with the biotechnology company Moderna and the Coalition for Epidemic Preparedness Innovation (CEPI) to develop what is known as a "messenger RNA" vaccine for the novel coronavirus.
- This type of gene-based vaccine does not contain live or inactivated virus. Our scientists took what they knew about the structure of the related SARS and MERS coronaviruses to quickly develop this novel vaccine.
- We anticipate the vaccine will be ready for clinical testing in the coming months, which would be a record turnaround. This first phase of clinical testing will involve giving the vaccine to healthy adults in the United States to see if it is safe and if it can induce an immune response in recipients.
- Scientists in our laboratories and at institutions that we fund across the U.S. are working on additional vaccine candidates.
- We have mobilized a rapid research response to quickly develop effective countermeasures for the novel coronavirus. However, we will not have a vaccine ready to distribute for some time as it will require numerous clinical trials to ensure a vaccine is safe and effective. Right now, the outbreak response remains focused on the proven public health practices of identifying cases, isolating patients and tracing contacts.

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: (b) (6)
(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 04:37:47 +0000
To: Graham, Barney (NIH/VRC) [E]
Subject: FW: updated CoV slides
Attachments: Updated CoV for ASF 27Jan2020.pptx

Sorry. Here they are. This is what happens when you have 600 e-mails in your in box

From: Graham, Barney (NIH/VRC) [E] (b) (6)
Sent: Monday, January 27, 2020 8:03 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Corbett, Kizzmekia (NIH/VRC) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Mascola, John (NIH/VRC) [E] <(b) (6)>; Morabito, Kaitlyn (NIH/VRC) [E] (b) (6)>
Subject: updated CoV slides

Updated CoV

BG

Barney S. Graham, MD, PhD
Senior Investigator
Deputy Director, Vaccine Research Center
Chief, Viral Pathogenesis Laboratory
National Institute of Allergy and Infectious Diseases, NIH
40 Convent Drive, MSC 3017
Bldg 40, Room 2502
Bethesda, MD 20892-3017
Phone: (b) (6)
URL: <https://www.niaid.nih.gov/research/barney-graham-md-phd>

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 23:58:30 +0000
To: Routh, Jennifer (NIH/NIAID) [E];Billet, Courtney (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E]
Subject: RE: Media Inquiry

Looks fine. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Routh, Jennifer (NIH/NIAID) [E] (b) (6) >
Sent: Monday, January 27, 2020 10:45 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Billet, Courtney (NIH/NIAID) [E] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Folkers, Greg (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6) >
Subject: RE: Media Inquiry

Dr. Fauci –

I have drafted responses to Radio Free Asia for your review. Please let me know if you have edits. I will share the final version with the reporter on your behalf and I will note the responses are attributed to you.

Can we make medicine and vaccine against that virus? And if so, how long do you think is it going to take?

NIAID, part of the U.S. biomedical research agency NIH, has mobilized a research response to 2019-nCoV that builds on experience with SARS-CoV, MERS-CoV and other emerging pathogens. Scientists are continuing basic research to characterize the novel virus and understand how it causes disease, as well as developing diagnostics, vaccines and treatments.

We have begun early stage development of an mRNA (messenger RNA) vaccine for 2019-nCoV. mRNA vaccines direct the body's cells to express a protein to elicit a broad immune response including high levels of neutralizing antibodies. The expressed protein is designed based on knowledge of the virus structure, but the platform does not contain live or inactivated virus. The mRNA platform can be quickly adapted and manufactured efficiently. NIAID and its industry partner Moderna anticipate the 2019-nCoV vaccine will be ready for the first stage of clinical testing in the coming months.

Do you think It will be even more lethal if that virus spread in a country with poor health environment such as North Korea?

At this stage it is difficult to predict how the virus will spread and cause disease in different regions. Experts around the globe are working to understand key epidemiological transmission features of 2019-nCoV and to characterize the severity and spectrum of disease. Certainly, a robust public health system that can effectively diagnose, isolate and care for patients and trace contacts is critical to controlling an emerging infectious disease.

Thanks,
Jen

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: (b) (6)
(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Sent: Sunday, January 26, 2020 9:57 PM
To: Billet, Courtney (NIH/NIAID) [E] (b) (6)
Cc: Routh, Jennifer (NIH/NIAID) [E] (b) (6) >
Subject: FW: Media Inquiry

Please have Jen prepare a response for me.

From: Albert Hong <honga@rfa.org>
Sent: Friday, January 24, 2020 10:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Media Inquiry

Hi,

I'm Albert Hong a reporter of the Radio Free Asia in Washington DC. I'm writing about new virus, called 2019 novel coronavirus (2019-nCoV). I want to ask you..

- 1)Can we make medicine and vaccine against that virus?
- 2)And if so, how long do you think is it going to take?
- 3)Do you think It will be even more lethal if that virus spread in a country with poor health environment such as North Korea?

Thank you and I'll be looking forward your comment.

Best,
Albert

Albert Hong

Broadcaster
Radio Free Asia- Korean Service
2025 M Street, NW., Washington DC 20036
Office (202) 266-4091

CONFIDENTIAL COMMUNICATION

This e-mail message is intended only for the use of the addressee and may contain information that is privileged and confidential. Any unauthorized dissemination, distribution, or copying is strictly prohibited.

If you receive this transmission in error, please contact network@rfa.org.

Visit us at www.rfa.org

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 31 Jan 2020 01:12:48 +0000
To: 彭丹妮
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Re:RE: Interview request from China Newsweek concerning 2019-nCoV

Dannie:

Sorry that I could not get back to you soon. I am swamped. Please try again.

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: 彭丹妮 <pengdanni@chinanews.com.cn>
Sent: Thursday, January 30, 2020 1:15 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Re:RE: Interview request from China Newsweek concerning 2019-nCoV

Hi Tony:

I am sorry for bothering again. This time I am writing on a piece analyzing the current situation of the 2019-nCoV. I would appreciate it very much if you could share some insights with me on the questions:

As of date 29th Jan, there are more than 7700 cases and 170 deaths reported in China. Virus spreads so fast in just one month.

1. The WHO is planning to reconvene a conference to decide if the 2019-nCoV constitute a PHEIC, what's your predictions on this result? and what this declaration means to China and the World?
2. Regarding the current public health reactions of Chinese government, what's your point of view? Do you think some steps deployed like isolating Wuhan, or building a fresh new hospital for critical patients, are they effective?

3. Comparing with SARS and MERS, what do you think the next few weeks will bring? I mean, What's your predictions about the results that this epidemic may finally brings and how it would end?

Dannie.

----- Original -----

From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6);
Date: Mon, Jan 27, 2020 05:56 AM
To: "彭丹妮" <pengdanni@chinanews.com.cn>;
Cc: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6); "Billet, Courtney (NIH/NIAID) [E]" (b) (6);
"Folkers, Greg (NIH/NIAID)[E]" (b) (6);
Subject: RE: Interview request from China Newsweek concerning 2019-nCoV vaccine

Dannie:

Thanks for the note. We are working on developing a vaccine for the 2019-nCoV here at NIH in collaboration with the Moderna Company. The vaccine will use a mRNA platform. We expect that we will be able to start Phase1 trials for safety in about 20 people within 3 months. However, that does not mean that a vaccine will be available for use and distribution in 3 months. It will take 3 additional months to get results and then we proceed to Phase 2 in a larger number of people. Even if we get emergency use authorization, it is highly unlikely that a vaccine will be available to actually use for at least 1 year. There are other companies developing vaccines in collaboration with us and with the Biomedical Advanced Research and Development Authority (BARDA) at the Department of Health and Human Services.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: 彭丹妮 <pengdanni@chinanews.com.cn>

Sent: Sunday, January 26, 2020 2:22 AM

To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]> (b) (6)

Subject: Interview request from China Newsweek concerning 2019-nCoV vaccine

Dear Dr. Fauci,

My name is Dannie, a science reporter from China Newsweek. I believe we had contacted before on the story of London Patient. Now I am covering the Wuhan Virus closely. For the moment, I am planning to write a piece of article about vaccine development. Thus I am writing to you, bearing the hope that you might share some insights with me.

1. Could you please introduce some basic information with me about the Wuhan Virus vaccine? How is the vaccine develop job going in your lab? who are the collaborative teams with you? Also, from the scientific side, how could the public understand the principles and purposes of this vaccine?
2. What's the challenges during your research and development process? when could the public expect it's usage in the market?
3. What are the other research teams that are undertaking this task expect you?

I am looking forward to your reply sincerely; Thank you so much.

Dannie.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 2 Feb 2020 17:22:51 +0000
To: Stephane Bancel; Mascola, John (NIH/VRC) [E]; Graham, Barney (NIH/VRC) [E]
Subject: RE: Moderna CoV vaccine update

Stephane:

Thanks for the follow-up... Good news!

Best regards,

Tony

From: Stephane Bancel [REDACTED] (b) (6)
Sent: Sunday, February 2, 2020 11:15 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>; Mascola, John (NIH/VRC) [E]
[REDACTED] (b) (6); Graham, Barney (NIH/VRC) [E] [REDACTED] (b) (6)>
Subject: Moderna CoV vaccine update

Gentlemen,

Just to let you know that the vaccine production is on track.

[REDACTED] (b) (4)

Cheers

stephane

 **Please consider the environment before printing this email**

Confidentiality notice and disclaimer: The information in this message and any attachments is intended for the exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, of any such information by persons or entities other than the intended addressee(s) is prohibited. If you have received this message in error and are not the intended addressee, please notify the sender immediately and delete this message and any attachments from your system without reading or disclosing them. If you are not the intended addressee, be

advised that any use of the information in this message and any attachment is prohibited and may be unlawful, and you must not copy this message or attachment or disclose the contents to any other person.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 14:34:57 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E]
Subject: RE: Requested coronavirus talking points for press conference
Attachments: Talking Points for NIAID Director Dr. Fauci - press conference - 02-06-2020 - Fauci Press remarks with tracked edits.docx

Oooops! Forgot the attachment. Here it is.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thursday, February 6, 2020 9:34 AM
To: Billet, Courtney (NIH/NIAID) [E] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6)>
Subject: RE: Requested coronavirus talking points for press conference

Here is my revised and updated press remarks with my tracked edits showing. Please accept edits, do a spell and grammar check and resubmit. Also, put a copy in my folder. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6) >
Sent: Thursday, February 6, 2020 9:16 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Folkers, Greg (NIH/NIAID) [E] (b) (6) >; Marston, Hilary (NIH/NIAID) [E] (b) (6) >; Routh, Jennifer (NIH/NIAID) [E] (b) (6) >; Stover, Kathy (NIH/NIAID) [E] <(b) (6)>
Subject: FW: Requested coronavirus talking points for press conference

HHS has asked us for your talking points for the press conference by 11am. We were planning to resubmit these. As was the case last time, this is a placeholder for the WH to know the outlines of what you would say. This is not a script.

Is it OK for us to send this to Bill?

From: Selgrade, Sara (NIH/NIAID) [E] (b) (6) >
Sent: Thursday, February 6, 2020 8:37 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Billet, Courtney (NIH/NIAID) [E] (b) (6) >; Routh, Jennifer (NIH/NIAID) [E] (b) (6) >; Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Subject: Requested coronavirus talking points for press conference

Dr. Fauci,

Attached please find the requested talking points from your last coronavirus press conference.

Please let us know if you need anything else.

Thanks,
Sara

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 7 Feb 2020 03:11:47 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Reporter working on coronavirus vaccine story

Let us discuss. Maybe over the weekend

From: Morris, Amanda <Amanda.Morris@gannett.com>
Sent: Thursday, February 6, 2020 4:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Reporter working on coronavirus vaccine story

Hi Anthony,

I hope this email finds you well! My name is Amanda Morris and I'm a bioscience reporter at the Arizona Republic, part of the USA Today network. I'm reaching out because I'm currently working on a story about how some ASU researchers (Brenda Hogue, Bert Jacobs and Shawn Chen) are trying to develop strategies to make a vaccine against the new coronavirus as well as a general platform they can use in the case of future new coronavirus strain outbreaks in humans.

I know globally there are many researchers trying to develop a vaccine for this new coronavirus, and that the NIH is working with Moderna to do so – and hopes to start testing with in a few months. I'm wondering if I can talk to you over the phone and ask a few questions about the work that NIH is doing, and what the broader challenges are for developing a vaccine? I'd like to have broader context about vaccines for our readers.

Please let me know as soon as possible. You can call or text me at (b) (6) Thank you!

All my best,
Amanda Morris

Bioscience Reporter for The Arizona Republic

Work phone: 602-444-8739

After hours and weekends, you can call or text my cell: (b) (6)

Email: amorris@gannett.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 7 Feb 2020 23:20:35 +0000
To: Stephane Bancel;Mascola, John (NIH/VRC) [E];Graham, Barney (NIH/VRC) [E]
Cc: Hamilton Bennett;Juan Andres
Subject: RE: Moderna update CoV Vaccine

Stephane:

Thank you for your note. I am very pleased that [REDACTED] (b) (4)

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stephane Bancel [REDACTED] (b) (6) >
Sent: Friday, February 7, 2020 5:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >; Mascola, John (NIH/VRC) [E] [REDACTED] (b) (6) >; Graham, Barney (NIH/VRC) [E] [REDACTED] (b) (6) >
Cc: Hamilton Bennett [REDACTED] (b) (6) >; Juan Andres [REDACTED] (b) (6)
Subject: Moderna update CoV Vaccine

Gentlemen,

Happy Friday

Just to let you know, the moderna [REDACTED] (b) (4) team [REDACTED] (b) (4) over the last few weeks.

[REDACTED] (b) (4) Fingers
crossed.

[Redacted] (b) (4)

[Redacted] (b) (4). We
are happy to [Redacted] (b) (4).

[Redacted] (b) (4)

Have a nice evening

Cheers

Stephane

 **Please consider the environment before printing this email**

Confidentiality notice and disclaimer: The information in this message and any attachments is intended for the exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, of any such information by persons or entities other than the intended addressee(s) is prohibited. If you have received this message in error and are not the intended addressee, please notify the sender immediately and delete this message and any attachments from your system without reading or disclosing them. If you are not the intended addressee, be advised that any use of the information in this message and any attachment is prohibited and may be unlawful, and you must not copy this message or attachment or disclose the contents to any other person.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 17:17:07 +0000
To: Stover, Kathy (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]
Subject: RE: FOR ASF REVIEW: Draft responses to questions from Italian news agency

See my edits in red.

From: Stover, Kathy (NIH/NIAID) [E] (b) (6)>
Sent: Friday, February 7, 2020 2:02 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6)
Subject: FOR ASF REVIEW: Draft responses to questions from Italian news agency

Hi Dr. Fauci,

Below are draft responses to questions from a reporter with the Italian news agency ANSA. Please let me know if you have any suggested edits, and I'll move it along.

Thanks,
Kathy

Enrica Battifoglia
Science and Technology Head Editor
ANSA news agency (Italian news)
Enrica.Battifoglia@ansa.it

Expected place of publication: ANSA Science web page (www.ansa.it/scienza)

Dear Professor Fauci,

I am Enrica Battifoglia of the Italian news agency ANSA, I already have had the pleasure to interview you several times at the AIDS world conferences.

I would like to ask you some questions about Coronavirus 2019-nCoV, to be published on the ANSA Science web page (www.ansa.it/scienza), the main online science news resource in Italy with over 1.5M contacts each month. I am sure that your clarity and competence will be highly valuable to put some much-needed order among so many contrasting news and data, and would be much appreciated by our readers.

1. Do the current available data allow to understand the threat level of coronavirus 2019-nCoV in terms of both lethality and diffusion speed, and about the possible evolution scenarios of the disease?

There is much that we do not know about the novel coronavirus. Currently, there have been more than 37,000 confirmed cases in China, and China has reported more than 800 deaths. As you know, there have been three confirmed cases in Italy to date. **The reported case fatality rate (lethality) among the 37,000 cases that have come to the attention of the health care system is 2%. However, given that there are likely many more cases that are without symptoms or with minimal symptoms, the actual death rate is probably lower than 2%.**

It is impossible to predict how the virus will evolve. It is our hope that the extraordinary containment measures that China has implemented will help **prevent** the outbreak from becoming a global pandemic. But given that the virus is present in 27 countries to date and can be transmitted from person-to-person, it may take a foothold and **evolve into a global pandemic.**

2) What exactly do we know about its modes of transmission, especially from people who do not yet have the symptoms?

Again, there is much that we do not know about the novel coronavirus, including its specific transmission abilities. Based on initial findings that have been reported, we suspect its transmission is similar to influenza and other respiratory viruses, namely that is transmitted through respiratory droplets when an infected person coughs or sneezes, and by touching surfaces, such as door handles, that **recently** have virus on them and then touching your face. There have also been reports that the virus **is present in feces and vomit. However, it is still uncertain that the virus can be transmitted through this route.**

Traditionally, most viruses are transmitted when someone has symptoms. With the novel coronavirus; however, there appears to be asymptomatic transmission occurring. We do not know how many cases are being driven by asymptomatic transmission or by those with symptoms. Typically, viruses are largely transmitted by infected people experiencing symptoms.

3) Are the genetic sequences provided by China enough to start working on a vaccine?

The genetic sequences provided by China enabled researchers to quickly develop a diagnostic that is being used to determine whether someone is infected with the novel coronavirus. The genetic information has also been useful in work to develop a preventive vaccine. The National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health, is building on its experience with the SARS and MERS coronaviruses to better understand the virus as well as develop and test rapid point-of-care diagnostics, vaccines and treatments, including broad-spectrum antivirals and antibody therapies. In terms of vaccines specifically, we are

working with the biotechnology company Moderna and the Coalition for Epidemic Preparedness Innovation (CEPI) to develop a “messenger RNA” vaccine for the novel coronavirus. Other countries and companies are working to develop a vaccine as well.

4) What are the technical times to develop a working vaccine in terms of scientific research, and what are the approx times for the necessary legal certifications, and for industrial production and distribution?

In terms of our work with Moderna and CEPI to develop a vaccine, we anticipate having an experimental vaccine ready for Phase 1 clinical trials within 2 to 3 months. This Phase 1 clinical trial will involve administering the vaccine to a small number of healthy adults in the United States to see if it is safe and has some ability to induce an immune response. If that is successful and the outbreak has not ended, we will move to a larger Phase 2 clinical trial with the expectation of **proving the efficacy (or not) of the vaccine within 1 to 1.5 years. If efficacious, it will still take additional months to produce enough vaccine to distribute widely..**

In addition to this vaccine, NIAID is also supporting scientists and companies to develop other vaccine candidates.

5) 2019-nCov is the third Coronavirus aggressive for humans that has appeared in the East in the last 20 years and in 2009 the virus responsible for the flu pandemic too did come from China: what sort of preventive measures could be practicable to reduce the risk of repetition of these events?

To clarify, the 2009 H1N1 influenza virus was first reported in Mexico, not China.

Viruses affecting humans have occurred throughout history, from the Bubonic Plague to the 1918 flu. We cannot predict what emerging infectious diseases will occur nor prevent the unknown from occurring in the first place. What we can do is learn as much as we can about emerging viruses, so that we can rapidly develop safe and effective point-of-care diagnostics, treatments and vaccines to protect against infection.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 14 Feb 2020 15:52:49 +0000
To: Strauss, Nicole
Cc: Mascola, John (NIH/VRC) [E];Graham, Barney (NIH/VRC) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: [REDACTED] (b) (4)
[REDACTED] (b) (4)

Nicole:

Thank you for your note and interest. I will copy on this e-mail Drs. John Mascola and Barney Graham of our Vaccine Research Center who are developing the vaccine with Moderna so that they can respond directly to you.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Strauss, Nicole [REDACTED] (b) (6) >
Sent: Friday, February 14, 2020 10:37 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Cc: Weisser, Karen [REDACTED] (b) (6)
Subject: [REDACTED] (b) (4)

Dear Dr. Anthony Fauci,

[REDACTED] (b) (4)

Best regards,
Nicole



Nicole Strauss

Pipeline Development & Innovation Lead

T: (b) (6) | M: (b) (6)

500 Arcola Road, Collegeville, PA 19426

[Website](#) | [LinkedIn](#)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 18 Feb 2020 22:06:38 +0000
To: Selgrade, Sara (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];NIAID OCGR Leg
Subject: RE: Requesting your assistance: Draft NIAID Statement for Upcoming Appropriations Hearings
Attachments: Draft_NIAID FY2021 Statement for the Record_to ASF - with Fauci tracked edits.docx

Here it is. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Selgrade, Sara (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, February 18, 2020 4:18 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6) >; Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>
Subject: Requesting your assistance: Draft NIAID Statement for Upcoming Appropriations Hearings

Dr. Fauci:

In preparation for the upcoming NIH budget hearings of the House and Senate Appropriations Subcommittees on Labor, HHS, Education, and Related Agencies, we have drafted the attached NIAID statement for the record, highlighting the topics that you previously selected.

We have a firm 3-page limit for the statement. It has been reviewed by the Divisions and Drs. Harper, Eisinger, Lerner, and Marston, as well as Courtney Billet, Martin Johnson, Greg Folkers, and Laurie Doepel.

NIH OLPA has asked to receive your statement by this Wednesday, Feb. 19th. Please let us know if you would like us to request additional time for your review, given competing priorities.

Thank you for your help.

Sara

Sara Selgrade, Ph.D.
Section Chief for Legislative Activities
Legislative Affairs and Correspondence Management Branch
Office of Communications and Government Relations
NIAID/NIH/DHHS
Bldg. 31, Room 7A17, MSC 2520
Bethesda, MD 20892-2520
Phone: (b) (6)
(b) (6)

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 20 Feb 2020 00:54:10 +0000
To: Crawford, Chase (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Haskins, Melinda (NIH/NIAID) [E];Selgrade, Sara (NIH/NIAID) [E]
Subject: RE: Requesting your assistance: Draft NIAID Insert for Upcoming Coronavirus Hearings
Attachments: Draft NIAID insert for COVID-19 hearings_to ASF - with Fauci tracked edits.docx

Here it is. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Crawford, Chase (NIH/NIAID) [E] (b) (6) >
Sent: Wednesday, February 19, 2020 6:16 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; Haskins, Melinda (NIH/NIAID) [E] (b) (6); Selgrade, Sara (NIH/NIAID) [E] (b) (6) >
Subject: Requesting your assistance: Draft NIAID Insert for Upcoming Coronavirus Hearings

Dr. Fauci:

In preparation for the upcoming COVID-19 hearings of the House Committee on Energy and Commerce Health Subcommittee and the Senate Committee on Health, Education, Labor and Pensions, we have drafted the attached NIAID insert for inclusion in the combined HHS statement for the record. The Department plans to use the same combined statement for both the House and Senate hearings.

The attached draft has been reviewed by the Divisions and Drs. Harper, Eisinger, Lerner, and Marston, as well as Courtney Billet, Martin Johnson, Greg Folkers, and Laurie Doepel.

The Department has asked to receive your statement by COB tomorrow, Feb. 20th.

Thank you for your help.

Chase

Chase Crawford, D.V.M., M.S.

Public Health Analyst

Legislative Affairs and Correspondence Management Branch

Office of Communications and Government Relations

NIAID/NIH/DHHS

Bldg. 31, Room 7A17, MSC 2520

Bethesda, MD 20892-2520

(b) (6)

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 25 Feb 2020 19:03:51 +0000
To: Ziady, Hanna (NE)
Subject: Re: Questions on coronavirus vaccine

45 people. It will take 3 to 4 months to complete.

On Feb 25, 2020, at 11:12 AM, Ziady, Hanna (NE) <Hanna.Ziady@turner.com> wrote:

Thanks very much for the quick response.

Do you know at this stage when the phase 1 trial will be completed and how many people will participate in it?

Many thanks,
Hanna

Hanna Ziady
Writer | CNN Business
O: +44 207 693 1884
M: (b) (6)
@hannaziady

From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >
Date: Tuesday, 25 February 2020 at 15:58
To: "Ziady, Hanna (NE)" <Hanna.Ziady@turner.com>
Subject: RE: Questions on coronavirus vaccine

The phase 1 trial to determine safety for the mRNA vaccine platform that NIH is doing with Moderna is scheduled to start within 2 months (some time in April). However, this is just the first step in attempting to have a vaccine available for use. Even proceeding at an emergency speed, a vaccine would not be available for use for at least 1 to 1.5 years. It is characterized as a "vaccine".

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Ziady, Hanna (NE) <Hanna.Ziady@turner.com>
Sent: Tuesday, February 25, 2020 5:56 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Questions on coronavirus vaccine

Dear Dr Fauci,

Trust this mail finds you well.

I have a few questions regarding the Moderna vaccine, which it would be great to get your input on.

Is it true that trials of the possible vaccine will start in April, but that, even if the first study is positive, the vaccine might not become widely available until next year because of the need for further studies and regulatory clearances?

The company is characterizing this as a vaccine. Strictly speaking, what should it be referred to as?

If you have time for a quick telephone call this morning as soon as you're able that would be great.

Many thanks,
Hanna

Hanna Ziady
Writer, CNN Business
Office: +44 207 693 1884
Mobile: [REDACTED] (b) (6)
@hannaziady

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are

incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 26 Feb 2020 17:33:08 +0000
To: Routh, Jennifer (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]
Subject: RE: remarks for White House press conference
Attachments: Fauci remarks Feb 26 - with minor edit.docx

I have made a minor tweak.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Routh, Jennifer (NIH/NIAID) [E] (b) (6) >
Sent: Wednesday, February 26, 2020 12:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6) >; Stover, Kathy (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Folkers, Greg (NIH/NIAID) [E] (b) (6) >; Marston, Hilary (NIH/NIAID) [E] (b) (6)
Subject: remarks for White House press conference

Dr. Fauci,

Attached for review are proposed remarks (in bullet format) for the White House press conference.

Thanks,
Jen

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C

Bethesda, MD 20892

Direct: (b) (6)

(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 16:25:41 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Mascola, John (NIH/VRC) [E];Lerner, Andrea (NIH/NIAID) [E]
Subject: RE: Background briefer
Attachments: 20200229_VRCModerna mRNA candidate briefer - with Fauci edits.docx

Here it is.

From: Marston, Hilary (NIH/NIAID) [E] (b) (6)>
Sent: Sunday, March 1, 2020 10:09 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Mascola, John (NIH/VRC) [E] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E] (b) (6)
Subject: Background briefer

ASF:

Attached please find a proposed background briefer for the visit to the VRC (big thanks to John, Barney, Kizzmekia , the rest of their team and Andrea and Greg). We focused on (b) (5)
(b) (5) VRC also prepared talking points for the round table should those be requested (I have those if you'd like to see them now, but so far the White House has not asked for this).

Available by cell. (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 13:56:21 +0000
To: Billet, Courtney (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]
Cc: Greg Folkers [REDACTED] (b) (6)
Subject: FW: Press release on Moderna FIH

fyi

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Richard Hatchett [REDACTED] (b) (6)
Sent: Tuesday, March 3, 2020 4:47 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Press release on Moderna FIH

Dear Tony,

I know everybody is moving fast and working at the boundaries of their capacity, [REDACTED] (b) (4)
[REDACTED] (b) (4)

Thanks -

Best regards,
Richard

RICHARD HATCHETT
CEO



(b) (6)

Visiting address: Gibbs building, 215 Euston Rd, Bloomsbury, London NW1 2BE, UK
Postal address: P.O. BOX 123, Torshov, 0412 Oslo, Norway

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 3 Mar 2020 13:56:36 +0000
To: Richard Hatchett
Subject: RE: Press release on Moderna FIH

Forwarded to our comms staff

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Richard Hatchett <(b) (6)>
Sent: Tuesday, March 3, 2020 4:47 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Press release on Moderna FIH

Dear Tony,

I know everybody is moving fast and working at the boundaries of their capacity, (b) (4)

(b) (4)

Thanks -

Best regards,
Richard

RICHARD HATCHETT
CEO



(b) (6)

Visiting address: Gibbs building, 215 Euston Rd, Bloomsbury, London NW1 2BE, UK

Postal address: P.O. BOX 123, Torshov, 0412 Oslo, Norway

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 9 Mar 2020 01:29:03 +0000
To: Barasch, Kimberly (NIH/NIAID) [C]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Moderna

Have me call this person tomorrow (Monday)

-----Original Message-----

From: EDWARD SCOLNICK [REDACTED] (b) (6)
Sent: Sunday, March 8, 2020 8:41 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Moderna

[REDACTED] (b) (4) I think they will. (b) (4) (1)
[REDACTED] than anyone thinks (b) (4) (1)
[REDACTED] (b) (4), (b) (6) I know what i am talking about If you get
this now, you can call me at home. Or in morning on my cell
Home [REDACTED] (b) (6). Cell [REDACTED] (b) (6). Ed scolnick

Sent from my iPad

From: [REDACTED] (b) (6)
Sent: Mon, 9 Mar 2020 19:56:20 -0400
To: Lane, Cliff (NIH/NIAID) [E]
Subject: Fwd: I learned today

This is Ed Skolnick. We should discuss

Begin forwarded message:

From: EDWARD SCOLNICK [REDACTED] (b) (6)
Date: March 9, 2020 at 7:20:40 PM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" [REDACTED] (b) (6)
Subject: I learned today

[REDACTED] (b) (4). I hope you
have literally every scientist at NIAID [REDACTED] (b) (4). I had a long conversation [REDACTED] (b) (4)

[REDACTED] It is possible [REDACTED] (b) (4)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 6 Jan 2020 16:20:12 +0000
To: Stephane Bancel;Mascola, John (NIH/VRC) [E];Graham, Barney (NIH/VRC) [E]
Subject: RE: Moderna 2019 shareholder letter

Stephane:

Thanks for sending this. I look forward to continuing our collaborations in 2020.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stephane Bancel (b) (6) >
Sent: Monday, January 6, 2020 8:24 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Mascola, John (NIH/VRC) [E] (b) (6) >; Graham, Barney (NIH/VRC) [E] (b) (6)
Subject: Moderna 2019 shareholder letter

Dear Tony, John and Barney,

Happy new year! Wishing you and your loved ones good health and happiness in 2020.

As usual, we used the holiday season to step back and assess our performance in 2019. I am pleased to share our 2019 shareholder letter in the PDF attached

I look forward to seeing you soon.

If you have any questions, please don't hesitate to contact me.

I hope that we will strengthen the collaborations between NIH and Moderna in 2020, and get to the clinic a vaccine together and work to get ready for pandemic readiness for many pathogens of interests.

Cheers,

Stephane

 **Please consider the environment before printing this email**

Confidentiality notice and disclaimer: The information in this message and any attachments is intended for the exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, of any such information by persons or entities other than the intended addressee(s) is prohibited. If you have received this message in error and are not the intended addressee, please notify the sender immediately and delete this message and any attachments from your system without reading or disclosing them. If you are not the intended addressee, be advised that any use of the information in this message and any attachment is prohibited and may be unlawful, and you must not copy this message or attachment or disclose the contents to any other person.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 6 Jan 2020 16:34:45 +0000
To: Mascola, John (NIH/VRC) [E]
Subject: RE: Moderna 2019 shareholder letter

Thanks, John.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mascola, John (NIH/VRC) [E] (b) (6)
Sent: Monday, January 6, 2020 9:53 AM
To: Erbeling, Emily (NIH/NIAID) [E] (b) (6); Cassetti, Cristina (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Graham, Barney (NIH/VRC) [E] (b) (6)>
Subject: RE: Moderna 2019 shareholder letter

Tony - Collaborations with Moderna continue to be productive.

Some highlights

(b) (4)

Moderna will also (b) (4)
We may engage them (b) (4)

I am forwarding this to Emily and Cristina – as we have a call this Friday to discuss collaborations with Moderna.

John

From: Graham, Barney (NIH/VRC) [E] (b) (6)>
Sent: Monday, January 6, 2020 9:13 AM
To: Stephane Bancel (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Mascola, John (NIH/VRC) [E] (b) (6)>
Subject: RE: Moderna 2019 shareholder letter

Thanks for sharing Stephane. We look forward to a productive and exciting year ahead.

Best wishes,

Barney

From: Stephane Bancel <(b) (6)>
Sent: Monday, January 6, 2020 8:24 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Mascola, John (NIH/VRC) [E] (b) (6)>; Graham, Barney (NIH/VRC) [E] (b) (6)>
Subject: Moderna 2019 shareholder letter

Dear Tony, John and Barney,

Happy new year! Wishing you and your loved ones good health and happiness in 2020.

As usual, we used the holiday season to step back and assess our performance in 2019. I am pleased to share our 2019 shareholder letter in the PDF attached

I look forward to seeing you soon.

If you have any questions, please don't hesitate to contact me.

I hope that we will strengthen the collaborations between NIH and Moderna in 2020, and get to the clinic a vaccine together and work to get ready for pandemic readiness for many pathogens of interests.

Cheers,

Stephane

 **Please consider the environment before printing this email**

Confidentiality notice and disclaimer: The information in this message and any attachments is intended for the exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure. Any

review, retransmission, dissemination or other use of, or taking of any action in reliance upon, of any such information by persons or entities other than the intended addressee(s) is prohibited. If you have received this message in error and are not the intended addressee, please notify the sender immediately and delete this message and any attachments from your system without reading or disclosing them. If you are not the intended addressee, be advised that any use of the information in this message and any attachment is prohibited and may be unlawful, and you must not copy this message or attachment or disclose the contents to any other person.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 15 Mar 2020 17:40:14 +0000
To: Folkers, Greg (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E];Billet, Courtney (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Cc: Marston, Hilary (NIH/NIAID) [E];Mascola, John (NIH/VRC) [E]
Subject: RE: Jen, Kathy, Courtney -- Monday's press release re: vaccine study

The Task Force has been changed to 10:00 AM tomorrow (Monday)

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Sent: Saturday, March 14, 2020 5:58 PM
To: Routh, Jennifer (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6); Billet, Courtney (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Cc: Marston, Hilary (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Mascola, John (NIH/VRC) [E] (b) (6)>
Subject: Jen, Kathy, Courtney -- Monday's press release re: vaccine study

I spoke with ASF.

He (or Sec or VP) would like to be able to announce the news of the first patient being vaccinated, at Monday's task force press conference.

Can you send the penultimate version of press release and alert the impacted folks -- Moderna, Kaiser in Seattle, CEPI, Bill Hall (others?),,,,,

Thank you!

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 10 Jan 2020 00:06:41 +0000
To: Stephane Bancel
Subject: RE: Moderna CMV interim clinical data after 3rd vaccination and announcement of Phase 2 start

Stephane:

Thank you for sharing this interesting and encouraging data.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stephane Bancel (b) (6)
Sent: Thursday, January 9, 2020 2:32 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Mascola, John (NIH/VRC) [E] (b) (6);> Graham, Barney (NIH/VRC) [E] (b) (6)>
Subject: Moderna CMV interim clinical data after 3rd vaccination and announcement of Phase 2 start

Dear Tony, John and Barney,

We just released new clinical data about our CMV vaccine

When we visited at VRC in September, we shared with you the data post 2nd vaccination. As you recall we achieved 2-5X seropositive titers in CMV seronegative subjects.

We are releasing today the 7 month interim data, post 3rd vaccination. Titers in sero negatives at 10X those of seropositives at baseline

We also announced today that the Phase 2 of CMV has dosed. Phase 3 start planned in 2021. (b) (4)

Enjoy. Working hard to take the CMV vaccine to market.

Cheers

Stephane

 **Please consider the environment before printing this email**

Confidentiality notice and disclaimer: The information in this message and any attachments is intended for the exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, of any such information by persons or entities other than the intended addressee(s) is prohibited. If you have received this message in error and are not the intended addressee, please notify the sender immediately and delete this message and any attachments from your system without reading or disclosing them. If you are not the intended addressee, be advised that any use of the information in this message and any attachment is prohibited and may be unlawful, and you must not copy this message or attachment or disclose the contents to any other person.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 16 Mar 2020 11:54:30 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: press release and "cheat sheet"
Attachments: NIAID press release mRNA Phase 1 FINAL.docx, CONDENSED mRNA phase 1 talking points 3.14 CB.docx

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)
Sent: Sunday, March 15, 2020 10:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6)
Subject: ASF: press release and "cheat sheet"

Attached, per discussion.

FOR IMMEDIATE RELEASE

Monday, March 16, 2020

Media Contact: Jennifer Routh
(301) 402-1663
NIAIDNews@niaid.nih.gov

Adults in the Seattle area who are interested in joining this study should visit <https://corona.kpwashingtoresearch.org/>. People who live outside of this region will not be eligible to participate in this trial.

NIH Clinical Trial of Investigational Vaccine for COVID-19 Begins
Study Enrolling Seattle-Based Healthy Adult Volunteers

A Phase 1 clinical trial evaluating an investigational vaccine designed to protect against coronavirus disease 2019 (COVID-19) has begun at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle. The [National Institute of Allergy and Infectious Diseases \(NIAID\)](#), part of the National Institutes of Health, is funding the trial. KPWHRI is part of NIAID's [Infectious Diseases Clinical Research Consortium](#). The open-label trial will enroll 45 healthy adult volunteers ages 18 to 55 years over approximately 6 weeks. The first participant received the investigational vaccine today.

The study is evaluating different doses of the experimental vaccine for safety and its ability to induce an immune response in participants. This is the first of multiple steps in the clinical trial process for evaluating the potential benefit of the vaccine.

The vaccine is called mRNA-1273 and was developed by NIAID scientists and their collaborators at the biotechnology company Moderna, Inc., based in Cambridge, Massachusetts. The Coalition for Epidemic Preparedness Innovations (CEPI) supported the manufacturing of the vaccine candidate for the Phase 1 clinical trial.

“Finding a safe and effective vaccine to prevent infection with SARS-CoV-2 is an urgent public health priority,” said NIAID Director Anthony S. Fauci, M.D. “This Phase 1 study, launched in record speed, is an important first step toward achieving that goal.”

Infection with SARS-CoV-2, the virus that causes COVID-19, can cause a mild to severe respiratory illness and include symptoms of fever, cough and shortness of breath. COVID-19 cases were first identified in December 2019 in Wuhan, Hubei Province, China. As of **date**, the [World Health Organization \(WHO\)](#) has reported **X** cases of COVID-19 and **X** deaths in **X**

countries or territories. **X** confirmed COVID-19 cases and **X** deaths have been reported in the United States, according to the [Centers for Disease Control and Prevention \(CDC\)](#).

Currently, no approved vaccines exist to prevent infection with SARS-CoV-2.

The investigational vaccine was developed using a genetic platform called mRNA (messenger RNA). The investigational vaccine directs the body's cells to express a virus protein that it is hoped will elicit a robust immune response. The mRNA-1273 vaccine has shown promise in animal models, and this is the first trial to examine it in humans.

Scientists at NIAID's Vaccine Research Center (VRC) and Moderna were able to quickly develop mRNA-1273 because of prior studies of related coronaviruses that cause severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Coronaviruses are spherical and have spikes protruding from their surface, giving the particles a crown-like appearance. The spike binds to human cells, allowing the virus to gain entry. VRC and Moderna scientists already were working on an investigational MERS vaccine targeting the spike, which provided a head start for developing a vaccine candidate to protect against COVID-19. Once the genetic information of SARS-CoV-2 became available, the scientists quickly selected a sequence to express the stabilized spike protein of the virus in the existing mRNA platform.

The Phase 1 trial is led by Lisa A. Jackson, M.D., senior investigator at KPWHRI. Study participants will receive two doses of the vaccine via intramuscular injection in the upper arm approximately 28 days apart. Each participant will be assigned to receive a 25 microgram (mcg), 100 mcg or 250 mcg dose at both vaccinations, with 15 people in each dose cohort. The first four participants will receive one injection with the low dose, and the next four participants will receive the 100 mcg dose. Investigators will review safety data before vaccinating the remaining participants in the 25 and 100 mcg dose groups and before participants receive their second vaccinations. Another safety review will be done before participants are enrolled in the 250 mcg cohort.

Participants will be asked to return to the clinic for follow-up visits between vaccinations and for additional visits across the span of a year after the second shot. Clinicians will monitor participants for common vaccination symptoms, such as soreness at the injection site or fever as well as any other medical issues. A protocol team will meet regularly to review safety data, and a safety monitoring committee will also periodically review trial data and advise NIAID. Participants also will be asked to provide blood samples at specified time points, which

investigators will test in the laboratory to detect and measure the immune response to the experimental vaccine.

“This work is critical to national efforts to respond to the threat of this emerging virus,” Dr. Jackson said. “We are prepared to conduct this important trial because of our experience as an NIH clinical trials center since 2007.”

Adults in the Seattle area who are interested in joining this study should visit <https://corona.kpwashingtongresearch.org/>. For more information about the study, visit [ClinicalTrials.gov](https://clinicaltrials.gov) and search identifier [NCT04283461](https://clinicaltrials.gov/ct2/show/study/NCT04283461).

NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the [NIAID website](#).

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

###

NIH...Turning Discovery Into Health®

Phase 1 trial of mRNA-1273

- Kaiser Permanente Washington Health Research Institute, Seattle
- PI: Lisa A. Jackson, M.D.
- 45 healthy adult volunteers ages 18 to 55 years
- First participant vaccinated on Monday, March 16, 2020 (tentative).
- Full enrollment expected to take approx. 6 weeks.
- Researchers could have initial data from the study within 3 months.

Funding:

- NIAID-VRC and Moderna developed the vaccine
- The Coalition for Epidemic Preparedness Innovations (CEPI) supported manufacturing
- NIAID is the regulatory sponsor and funded Kaiser Permanente to conduct the trial through the Infectious Diseases Clinical Research Consortium (IDCRC) infrastructure.

Objective:

- To evaluate different doses of the experimental vaccine for safety and ability to induce an immune response.
- It is important to note that this is the first of multiple steps in the clinical trial process.
- This trial will **not** examine if the vaccine can provide protection from SARS-CoV-2
- If the vaccine shows promise, the next step is a trial enrolling several hundred people to learn more about safety and immunogenicity, followed by a trial of several thousand people, including placebo recipients, to understand if the vaccine is protective.
- A COVID-19 vaccine will not be widely available to the public for at least a year and likely longer. Clinical testing to establish a vaccine's safety and efficacy takes time.

Design:

- Participants will receive two doses of the experimental vaccine via intramuscular injection in the upper arm approximately 28 days apart.
- Each participant will be assigned to receive either a 25 mcg, 100 mcg or 250 mcg dose at both vaccinations. 15 participants per dose cohort.
- The first four participants will receive one injection with lowest dose. Next four participants receive 100 mcg dose.
- The protocol team will then review safety data before vaccinating the remaining participants in the 25 and 100 mcg dose groups and before participants receive their second vaccinations. Another safety review will be conducted before participants are enrolled in the 250 mcg cohort.
- Participants will return to clinic for multiple follow-up visits between vaccinations and for a year after second vaccination. Participants will provide blood samples throughout the trial, which will be used to measure immune response to the vaccine.

Trial safety oversight:

- Clinical staff will monitor participants for soreness at the injection site, fever, etc.
- A protocol team will meet regularly to review safety data.
 - An independent safety monitoring committee will also periodically review trial data and advise NIAID.

The investigational vaccine:

- mRNA-1273 was developed by NIAID scientists and collaborators at Moderna, Inc.
- NIAID and Moderna were able to quickly develop mRNA-1273 thanks to their prior studies of related coronaviruses that cause SARS and MERS.
- The vaccine cannot cause COVID-19 because it only uses one protein from the virus.
- The vaccine was not developed using traditional vaccine approaches such as a live-attenuated (weakened) virus vaccine or an inactivated whole virus vaccine. Instead, it was made using the genetic code the virus uses to make the spike protein and delivered as mRNA (messenger RNA) using a manufacturing platform developed by Moderna.
- The genetic code directs the body's cells to express a virus protein that is anticipated to elicit a robust immune response.
- About the protein:
 - Coronaviruses are spherical and have spike proteins protruding from their surface, giving the particles a crown-like appearance.
 - The spike binds to human cells, allowing the virus to gain entry.
 - Once the genetic information of SARS-CoV-2 became available, the vaccine developers quickly selected a sequence based on their prior work to express the stabilized spike protein of the virus in the mRNA platform.
- The mRNA-1273 vaccine has shown promising immune responses in animal models, and this is the first trial to examine it in humans.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 13 Jan 2020 20:43:25 +0000
To: Conrad, Patricia (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Wuhan coronavirus overview
Attachments: Wuhan Coronavirus Update 1.10.2020.docx

Print out for PCC folder. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Marston, Hilary (NIH/NIAID) [E] (b) (6) >
Sent: Friday, January 10, 2020 5:16 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Cc: Bushar, Nicholas (NIH/NIAID) [E] (b) (6)
Subject: Wuhan coronavirus overview

With input from divisions and budget, Nick and I put together the attached brief overview of our *existing* (mainly MERS) coronavirus work. I will also put in disease info.

Hilary D. Marston, MD, MPH
Medical Officer and Policy Advisor for Global Health
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
Cell: (b) (6)
Email: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 16 Mar 2020 21:25:19 +0000
To: Mascola, John (NIH/VRC) [E];Stephane Bancel;Graham, Barney (NIH/VRC) [E]
Cc: Erbelding, Emily (NIH/NIAID) [E]
Subject: RE: Congratulation on dosing today. Cant wait to see the titers in human and if they are neutralizing.

Congratulations to all. However, we have only completed (b) (4)

(b) (4)

(b) (4) The latter will be the challenge. If we are fortunate enough to have (b) (4). I hope that we have (b) (4) I am telling you thing that you already know, but we need to all pull for that goal.

From: Mascola, John (NIH/VRC) [E] (b) (6)
Sent: Monday, March 16, 2020 3:01 PM
To: Stephane Bancel <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6); Graham, Barney (NIH/VRC) [E] (b) (6)
Cc: Erbelding, Emily (NIH/NIAID) [E] (b) (6)
Subject: RE: Congratulation on dosing today. Cant wait to see the titers in human and if they are neutralizing.

Stephane,

(b) (4)

John

From: Stephane Bancel (b) (6)>
Sent: Monday, March 16, 2020 2:34 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Mascola, John (NIH/VRC) [E] (b) (6)>; Graham, Barney (NIH/VRC) [E] (b) (6)>
Subject: Congratulation on dosing today. Cant wait to see the titers in human and if they are neutralizing.

 **Please consider the environment before printing this email**

Confidentiality notice and disclaimer: The information in this message and any attachments is intended for the exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, of any such information by persons or entities other than the intended addressee(s) is prohibited. If you have received this message in error and are not the intended addressee, please notify the sender immediately and delete this message and any attachments from your system without reading or disclosing them. If you are not the intended addressee, be advised that any use of the information in this message and any attachment is prohibited and may be unlawful, and you must not copy this message or attachment or disclose the contents to any other person.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Jan 2020 22:14:02 +0000
To: Mascola, John (NIH/VRC) [E]
Subject: RE: Coronavirus: Oy vey

John:

Can you call me at (b) (6) It will take only a minute.
Thanks,
Tony

-----Original Message-----

From: Mascola, John (NIH/VRC) [E] (b) (6)>
Sent: Monday, January 20, 2020 5:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Graham, Barney (NIH/VRC) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: FW: Coronavirus: Oy vey

Tony,

One item to point out is that while this falls exactly into Barneys predicted framework for pandemic response; i.e. a new Betacoronavirus - there are some risks to success.

Barney and team know how to express MERS and SARS viral spikes - using structural information to introduce a key stabilizing mutation. We think the same mutation will apply here - but we need to express the protein and test.

We think the likelihood of success is high enough - that we should move full speed ahead to make the mRNA.

We can stop by to update you in more scientific detail if useful

John

-----Original Message-----

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Sent: Monday, January 20, 2020 1:32 PM
To: Jon LaPook (b) (6)>
Cc: amb@cbsnews.com; Kevin Finnegan <kpf@cbsnews.com>; Leigh Winick <WinickL@cbsnews.com>; Angelica Fusco <fuscoa@cbsnews.com>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Mascola, John (NIH/VRC) [E] (b) (6)>; Graham, Barney (NIH/VRC) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6)>
Subject: RE: Coronavirus: Oy vey

Jon:

We are working with the Moderna company to put the gene for the spike protein of the 2019 n-CoV into an mRNA platform to develop a vaccine to go into Phase 1 trials. We did it with Zika with DNA in 3.25 months. We can probably go from sequence to Phase 1 with the mRNA platform in about 2 months. We are doing this at the Vaccine Research Center that you have previously visited. We can certainly arrange for you to visit some time and see directly what we are doing.

Best regards,
Tony

-----Original Message-----

From: Jon LaPook (b) (6)>
Sent: Monday, January 20, 2020 1:21 PM

To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Cc: amb@cbsnews.com; Kevin Finnegan <kpf@cbsnews.com>; Leigh Winick <WinickL@cbsnews.com>;
Angelica Fusco <fuscoa@cbsnews.com>
Subject: Coronavirus: Oy vey

Hi Tony,
Deja vu all over again.
Of course, I'm following along closely. If there is an opportunity for me to get an inside look at what you and your team are doing, please let me know.

Thanks,
Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 21 Mar 2020 22:57:49 +0000
To: Collins, Francis (NIH/OD) [E]
Cc: Mascola, John (NIH/VRC) [E]; (b) (6); Marston, Hilary (NIH/NIAID) [E]; Auchincloss, Hugh (NIH/NIAID) [C] ((b) (6))
Subject: FW: Moderna CoV vaccine update

Francis:

Stephane is enthusiastic, but a bit hyperkinetic. John Mascola, Cliff, Hugh Auchincloss, Hilary Marston and I are working many channels (b) (4)

(b) (6) He should not be bothering you with this.

Best,
Tony

From: Collins, Francis (NIH/OD) [E] (b) (6)
Sent: Saturday, March 21, 2020 6:19 PM
To: Stephane Bancel (b) (6)
Cc: Lane, Cliff (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: RE: Moderna CoV vaccine update

Hi Stephane,

I'm delighted to see the remarkably rapid progress of the VRC-Modern vaccine. And the schedule you mention sounds encouraging. I would have thought that (b) (4) would be well suited (b) (4) problem there?

Best, Francis

From: Stephane Bancel (b) (6)>
Sent: Saturday, March 21, 2020 5:32 PM
To: Collins, Francis (NIH/OD) [E] (b) (6)>
Subject: Moderna CoV vaccine update

Francis. Quick update.

As you know the phase 1 has started
We Have a plan with fda To start a large phase 2 in May as soon as we have immunogenicity data from phase 1

We will start phase 3 in the Summer

At moderna we are working [REDACTED] (b) (6)
[REDACTED] as the US government will decide.

[REDACTED] (b) (6)

We did phase 1 in 63 days from sequence. Nobody believed we can.

We will start phase 2 in May.

The vaccine has a high chance of working. Barnay Graham's made it work for MERS.

Our CMV vaccine work. Our flu vaccines work.

[REDACTED] (b) (4)

Call me if you need clarification

[REDACTED] (b) (6)

Cheers

Stephane

Get [Outlook for iOS](#)

 **Please consider the environment before printing this email**

Confidentiality notice and disclaimer: The information in this message and any attachments is intended for the exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, of any such information by persons or entities other than the intended addressee(s) is prohibited. If you have received this message in error and are not the intended addressee, please notify the sender immediately and delete this message and any attachments from your system without reading or disclosing them. If you are not the intended addressee, be advised that any use of the information in this message and any attachment is prohibited and may be unlawful, and you must not copy this message or attachment or disclose the contents to any other person.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 23 Mar 2020 01:23:55 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]; (b) (6)
Subject: FW: Possible agenda for Wednesday
Attachments: COVID-19 TransNIH_032520 hm.docx

Please take the lead in putting together slides for Wednesday. If I can make it (which is uncertain), I will need them to make a presentation.

Thanks,\Tony

From: Marston, Hilary (NIH/NIAID) [E] <(b) (6)>
Sent: Sunday, March 22, 2020 7:10 PM
To: Collins, Francis (NIH/OD) [E] (b) (6)
Cc: Tabak, Lawrence (NIH/OD) [E] (b) (6); Wolinetz, Carrie (NIH/OD) [E] (b) (6); Anderson, James (NIH/OD) [E] <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6)
Subject: Re: Possible agenda for Wednesday

Thanks for the chance to weigh in. I have it blocked on my calendar and would look forward to the discussion. And I'm happy to pull slides together as outlined.

Here are some minor comments on the agenda, which looks excellent.

Looking forward to it,

Hilary

From: "Collins, Francis (NIH/OD) [E]" (b) (6)
Date: Sunday, March 22, 2020 at 5:09 PM
To: Hilary Marston (b) (6)>
Cc: "Tabak, Lawrence (NIH/OD) [E]" (b) (6), "Wolinetz, Carrie (NIH/OD) [E]" (b) (6), "Anderson, James (NIH/OD) [E]" (b) (6), Anthony Fauci (b) (6)>, Henry Lane (b) (6)>
Subject: Possible agenda for Wednesday

Hi Hilary,

I've been through the COVID-19 ideas collected from your Deputies meeting, plus reaching out for a few other inputs. What I hope to do is to assemble this into a lively three-hour discussion on Wednesday afternoon (2 - 5 PM). Tony is enthusiastic about our doing this, but his presence is unfortunately doubtful, given all of the other demands he faces. I'm counting on you and Cliff to be there, however – is this etched on your calendars?

Please see attached for my rather rough first attempt at an agenda. It's a lot of topics and the list will probably need to be culled – but I am trying to give each IC that has some interest the chance to put something forward, using 2 minutes and a single slide. For NIAID, I would hope you could outline the current portfolio of efforts at the beginning of each theme, using 1 – 4 slides (since NIAID has a lot more going on).

I would want there to be time for discussion in each theme, so that other ideas could be floated.

Please let me know your thoughts, ideally this evening. I'm also asking for input from others who are cc'd here.

Best, Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Jan 2020 22:40:52 +0000
To: Redfield, Robert R. (CDC/OD);Messonnier, Nancy (CDC/DDID/NCIRD/OD)
Subject: 2019 n-CoV vaccine FYI

Bob/Nancy:

Just as an FYI and to follow-up my conversation with Bob, our team at the NIAID Vaccine Research Center (Barney Graham, John Mascola et al) have already started on the steps to develop a vaccine for the 2019 n-CoV. We have the available sequence and are partnering with the Moderna Company to insert the gene for the spike protein of the virus into the mRNA platform. If all goes well (80-85% chance) we should be able to have a Phase 1 trial going in 2 to 3 months. We did this with SARS using a DNA platform and never had to go beyond phase 1. Let us hope that this will be the case with the n-CoV. Thanks.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 28 Mar 2020 17:38:17 +0000
To: Johnson, Martin S. (NIH/NIAID) [E]; Auchincloss, Hugh (NIH/NIAID) [E]; NIAID OCGR Leg; McGowan, John J. (NIH/NIAID) [E]; Harper, Jill (NIH/NIAID) [E]; Crum, Wayne (NIH/NIAID) [E]; Erbelding, Emily (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]; Rotrosen, Daniel (NIH/NIAID) [E]
Cc: Eisinger, Robert (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]; Lerner, Andrea (NIH/NIAID) [E]; Doepel, Laurie (NIH/NIAID) [E]; Gilles, Sharon (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]; Law, Kim (NIH/NIAID) [E]; Lee, Kun-Lin (NIH/NIAID) [E]; Bushar, Nicholas (NIH/NIAID) [E]; Schneider, Johanna (NIH/NIAID) [E]
Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 3/26/20

Thanks, Martin.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Johnson, Martin S. (NIH/NIAID) [E] (b) (6)
Sent: Friday, March 27, 2020 7:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] (b) (6)>; Harper, Jill (NIH/NIAID) [E] (b) (6)>; Crum, Wayne (NIH/NIAID) [E] (b) (6); Erbelding, Emily (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Rotrosen, Daniel (NIH/NIAID) [E] (b) (6)
Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E] (b) (6)>; Doepel, Laurie (NIH/NIAID) [E] (b) (6)>; Gilles, Sharon (NIH/NIAID) [E] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6)>; Law, Kim (NIH/NIAID) [E] (b) (6); Lee, Kun-Lin (NIH/NIAID) [E] (b) (6)>; Bushar, Nicholas (NIH/NIAID) [E] (b) (6)

Schneider, Johanna (NIH/NIAID) [E] (b) (6)

Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 3/26/20

Tony,

YTD spending is \$21.6M , a weekly increase of \$4.0M for clinical trial site set-up for therapeutics, further vaccine development, small animal development, and therapeutic development (mAbs) and basic research.

Most of the (b) (5) we listed last week we expect to be awarded before March 31. In many cases contractors have begun work without the award so as to not stall work.

Early next week I'll provide a summary spending plan for the additional \$706M that NIAID received in the supplemental appropriation signed by the President today.

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]

Sent: Friday, March 20, 2020 4:54 PM

To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] (b) (6); Harper, Jill (NIH/NIAID) [E] (b) (6); Crum, Wayne (NIH/NIAID) [E] (b) (6); Erbelding, Emily (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6)

Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] <(b) (6)>; Doepel, Laurie (NIH/NIAID) [E] (b) (6); Gilles, Sharon (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Law, Kim (NIH/NIAID) [E] (b) (6); Lee, Kun-Lin (NIH/NIAID) [E] (b) (6); Bushar, Nicholas (NIH/NIAID) [E] (b) (6); Schneider, Johanna (NIH/NIAID) [E] (b) (6)

Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 3/19/20

Tony,

YTD spending is \$17.6M , a weekly increase of \$3.5M for clinical trial site set-up, therapeutic development (mAbs) and basic research.

In the next 1-2 weeks we will see a surge in spending of ~ (b) (5) to support several activities including RCTs of therapeutics, observational studies and advancing interventions. Further detail is provided below:

- (b) (5) to start RCT of investigational therapeutics in patients with early disease
- (b) (5) to begin development and RCT of IVIG in patients with COVID-19

- (b) (5) to support project management and overall support for adaptive RCT of investigational therapeutics. Includes site start-up activities, protocol implementation, safety monitoring and virology testing
- (b) (5) to start implementation of observational study to characterize patients with COVID-19
- (b) (5) to support extramural investigators in basic, vaccine and therapeutic research
- for contracts to develop animal models, distribute reagents and develop vaccines
- for infrastructure and administration including staffing to handle surge in communications

We greatly appreciate all your hard work.

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, March 13, 2020 6:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] (b) (6); Harper, Jill (NIH/NIAID) [E] (b) (6); Crum, Wayne (NIH/NIAID) [E] (b) (6); Erbelding, Emily (NIH/NIAID) [E] (b) (6)
Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6); Doepel, Laurie (NIH/NIAID) [E] (b) (6); Gilles, Sharon (NIH/NIAID) [E] <(b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Law, Kim (NIH/NIAID) [E] (b) (6); Lee, Kun-Lin (NIH/NIAID) [E] (b) (6); Bushar, Nicholas (NIH/NIAID) [E] (b) (6); Schneider, Johanna (NIH/NIAID) [E] (b) (6)
Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 3/12/20

Tony,

Since we our last report we have increased spending on the COVID-19 response by \$1.5M for a total YTD spending of \$14.1M.

The \$1.5M increase is for the following:

\$1.0M awarded to set-up clinical sites at Emory and U. Washington Seattle for adaptable RCT of remdesivir.

\$0.4M supported data analysis of rhesus animal model and grant to gain understanding of the host pathways that regulate viral gene expression and viral subversion of the host immune system.

\$0.1M funded vaccine development at VRC and DIR

In the next two weeks we should see an increase of (b) (4). Significant planned items are as follows:

- ~ (b) (4) - Set-Up of additional study sites for the adaptive clinical trial of the investigational antiviral remdesivir.
- ~ (b) (4) to support CEIRS site (St. Judes) for human host factor and disease severity studies, human-animal interface, and animal surveillance in areas at high risk of spillover including Africa
- ~ (b) (4) - awards to extramural investigators including applications in response to the Notice of Special Interest (NOSI) for COVID-19.
- (b) (4) to identify and characterize human mAb derived from acute and convalescent COVID-19 patients, to define protective antibodies that can be developed as therapeutics or used in diagnostic testing (Daved Fremont, Michael Diamond Washington University, St. Louis; Patrick Wilson, U . Chicago)

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, March 6, 2020 5:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] (b) (6); Harper, Jill (NIH/NIAID) [E] (b) (6)>; Crum, Wayne (NIH/NIAID) [E] (b) (6)>
Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6); Doepel, Laurie (NIH/NIAID) [E] (b) (6)>; Gilles, Sharon (NIH/NIAID) [E] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Law, Kim (NIH/NIAID) [E] (b) (6); Lee, Kun-Lin (NIH/NIAID) [E] (b) (6)
Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 3/5/20

Tony,

Since we our last report we have increased spending on the COVID-19 response by \$0.2M for a total YTD spending of \$12.6M.

The \$0.2M increase is for vaccine candidate development at NIAID Intramural Labs including RML. Costs are mostly for staffing and overhead and include a preclinical immunogenicity study designed to test the mRNA-1273 nCoV vaccine two-dose schedule in mice. The study will measure the immune response to this vaccine in an animal model in anticipation of clinical test in humans.

In the next two weeks we should see an increase of (b) (5). Significant planned items are as follows:

- (b) (5) - Set-Up of study sites for the adaptive clinical trial of the investigational antiviral remdesivir. We are now working on making supplemental awards to Washington University, Seattle, University of Nebraska Medical Center (UNMC) and Baylor, who will conduct the trial at UTMB Galveston.
- ~ (b) (5) - awards to extramural investigators including applications in response to the Notice of Special Interest (NOSI) for COVID-19.
- (b) (5) to Daved Fremont, Michael Diamond Washington University, St. Louis; Patrick Wilson, U . Chicago for human mAb production and characterization (for use as therapeutics or diagnostics; from different patients than being screened by Dr. Crowe)

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, February 28, 2020 11:57 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] (b) (6); Harper, Jill (NIH/NIAID) [E] (b) (6); Crum, Wayne (NIH/NIAID) [E] (b) (6);
Cc: Eisinger, Robert (NIH/NIAID) [E] <(b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6); Gilles, Sharon (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Law, Kim (NIH/NIAID) [E] (b) (6); Lee, Kun-Lin (NIH/NIAID) [E] (b) (6)
Subject: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 2/27/20

Tony,

Since we our last report we have increased spending on the COVID-19 response by \$2.3M for a total YTD spending of \$12.4M.

A recap of the \$2.3 million spent in the last week is as follows:

- \$1.9M to set-up a Phase I trial (45 subjects) of the VRC/Moderna mRNA platform candidate at Kaiser Permanente Washington Health Research Institute (One of the VTEUs)
- \$0.3M that supported University of Hong Kong researchers in the development of a RT-PCR test to detect SARSCoV2 from human samples. The group has now shared the tests and relevant reagents with over 30 labs globally to enable diagnosis of COVID-19.
- \$0.1M vaccine candidate development at NIAID Intramural Labs

In the next two weeks we should see an increase of (b) (5). Significant spending items are as follows:

- (b) (5) - Set-Up of study sites for the adaptive clinical trial of the investigational antiviral remdesivir. We are now working on making supplemental awards to University of Nebraska Medical Center (UNMC) and Baylor, who will conduct the trial at UTMB Galveston.
- ~ (b) (5) - awards to extramural investigators including applications in response to the Notice of Special Interest (NOSI) for COVID-19.

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, February 14, 2020 3:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] (b) (6); Harper, Jill (NIH/NIAID) [E] <(b) (6)>; Crum, Wayne (NIH/NIAID) [E] <(b) (6)>
Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6); Gilles, Sharon (NIH/NIAID) [E] <(b) (6)>
Subject: FY 2020 - COVID-19 - Actual and Forecasted Spending as of 2/13/20

Dr. Fauci,

Attached is a narrative we are updating weekly for NIAID's COVID-19 response.

The accompanying spreadsheet summarizes the figures and includes a summary of our supplemental request.

We'll provide an update by Thursday of next week.

Martin

Resource Planning and Mission Integration Branch (RPMIB) – NIAID
NIH Bldg. 31 Room 7A47
Tel: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Jan 2020 18:30:52 +0000
To: Collins, Francis (NIH/OD) [E]
Subject: RE: update on coronavirus?

Indeed, it happened 15 minutes after I sent you the e-mail. Embargoed until 3:00 PM ET

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Tuesday, January 21, 2020 1:28 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Re: update on coronavirus?

Thanks. Larry just gave me a heads up that your last sentence may have come true in WA.

Sent from my iPhone

On Jan 21, 2020, at 5:13 PM, Fauci, Anthony (NIH/NIAID) [E] (b) (6) wrote:

Francis:

Thanks for the note. There is definite person-to-person transmission. 15 health care workers were infected in a Wuhan Hospital. We do not know about the degree of "sustained" person-to-person transmission. There have been 298 cases reported as of this AM with 6 deaths. The number is likely larger and is growing by the hour. We have already started working on a vaccine for the 2019 n-CoV. We are partnering with the Moderna Company using their mRNA vaccine

platform. We should be in Phase 1 trials (unless there are unforeseen issues) within 3 months. We are also pursuing any cross-reactivity of mAbs that we developed for SARS to see if they could be used as therapeutics for n-CoV. Other drugs such as remdesivir and ritonavir have been tried with MERS and may be useful. We would however, need the isolates (we just have sequence) to test these. We are already screening entries from China at JFK, LAX and SFO. I would not be surprised if just like SARS and MERS we ultimately see an imported case in the USA.

Hope that this is helpful.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Tuesday, January 21, 2020 10:59 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: update on coronavirus?

Hi Tony,

I will be in a Davos session on Thursday where response to the coronavirus outbreak will be a topic. Paul Stoffels will be there, as will Tedros.

What's now the best information about person-to-person transmission and mortality risk? Can you give me a quick precis of what the US is doing about risks of the illness coming to our shores? What do we know about possible therapies? And what is the plan to utilize the fastest possible platform to work on a vaccine?

Thanks, and sorry to hit you with this!

Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 7 Apr 2020 13:42:04 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Greg Folkers [REDACTED] (b) (6)
Subject: FW: Keynote Speaker Invitation - 8th International mRNA Health Conference

No!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6) > **On Behalf Of** Fauci, Anthony (NIH/NIAID) [E]
Sent: Tuesday, April 7, 2020 9:33 AM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: Keynote Speaker Invitation - 8th International mRNA Health Conference

From: Pardi, Norbert [REDACTED] (b) (6)
Sent: Tuesday, April 7, 2020 9:07 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Keynote Speaker Invitation - 8th International mRNA Health Conference

Dear Dr. Fauci,

On behalf of the organizing committee, **I am writing to invite you to Keynote the 8th International mRNA Health Conference** (<http://www.mrna-conference.com/>) to be held at the Boston Park Plaza Hotel on Nov 9-10, 2020.

The International mRNA Health Conference is a yearly non-profit event collaboratively organized by Curevac, BioNTech and Moderna. It brings together academic and industry thought leaders in the mRNA design and delivery space to explore the rapidly evolving science, business and regulatory landscape of mRNA medicines. Over the last seven years, this 2-day conference has become the premier destination for industry and academic professionals to network with colleagues, learn about the latest advances in mRNA technology, and to attend scientific presentations given by the most esteemed experts in the field. Notably, it is the only annual conference dedicated solely to mRNA therapeutics.

As a scientist with tremendous experience and the director of NIAID, the organizing committee thought that conference attendees would very much appreciate hearing about your thoughts about mRNA therapeutics, particularly vaccines, and any perspectives you wish to share.

The organizing committee recognizes that your calendar is likely filled years in advance, but we all have our fingers crossed that you might be able to fit this into your busy schedule.

I look forward to hearing from you.

all best wishes,

Norbert

P.S. In the event that the COVID-19 crisis is still curtailing travel in the fall, our backup plan would be to have a completely virtual meeting on the same dates. We plan to make that decision in late August/early September.

Norbert Pardi, Ph.D.

Research Assistant Professor of Medicine

Infectious Disease Division

Perelman School of Medicine

University of Pennsylvania

Philadelphia, PA 19104

PH: [REDACTED] (b) (6)

[REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 10:53:30 +0000
To: Mascola, John (NIH/VRC) [E];Graham, Barney (NIH/VRC) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: My mobile info

As you can see, Stephane is very enthusiastic about working with us.

From: Stephane Bancel [REDACTED] (b) (6) >
Sent: Tuesday, January 21, 2020 11:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6); Nadege Ripley [REDACTED] (b) (6)
Subject: Re: My mobile info

Thank you Tony.

You are moderna team full commitment.

Don't hesitate to call at anytime. I copy also nadege who runs my office and always know how to find me

Cheers. Stephane

Get [Outlook for iOS](#)

From: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Sent: Wednesday, January 22, 2020 04:05
To: Stephane Bancel
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: My mobile info

Stephane:

Thanks for the note. My office number is [REDACTED] (b) (6) and my cell phone number is [REDACTED] (b) (6)

[REDACTED] We look forward to working with you on this important issue.

Best regards,

Tony

From: Stephane Bancel [REDACTED] (b) (6)
Sent: Tuesday, January 21, 2020 8:30 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: My mobile info

Dear Tony

i have stayed close to my team on nCoV.

We look forward to helping do the right thing and helping as much as we can.

My mobile is [REDACTED] (b) (6) in case you need to reach me. It might be useful if you are comfortable to give me your mobile number too so that I can text you and call you if I need to reach to you. We both know that every hour counts.

As you might know CEPI is in contact with us.

Once we have a formal plan (I know our team are talking Thursday. Maybe they should talk Wednesday) it might be helpful to communicate together the game plan.

Cheers

Stephane

Get [Outlook for iOS](#)

 **Please consider the environment before printing this email**

Confidentiality notice and disclaimer: The information in this message and any attachments is intended for the exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, of any such information by persons or entities other than the intended addressee(s) is prohibited. If you have received this message in error and are not the intended addressee, please notify the sender immediately and delete this message and any attachments from your system without reading or disclosing them. If you are not the intended addressee, be advised that any use of the information in this message and any attachment is prohibited and may be unlawful, and you must not copy this message or attachment or disclose the contents to any other person.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 10:54:41 +0000
To: Mascola, John (NIH/VRC) [E];Graham, Barney (NIH/VRC) [E]
Cc: NIAID OD AM
Subject: FW: CEPI. NIH. Moderna.

Let us discuss.

From: Stephane Bancel <[REDACTED] (b) (6)>
Sent: Wednesday, January 22, 2020 12:55 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>; Richard Hatchett
[REDACTED] (b) (6)>
Subject: CEPI. NIH. Moderna.

Dear Tony,

I just spoke to Richard at CEPI. We are both in Europe at davos. We are finalizing, hopefully over the next 24-48h a grant from CEPI to moderna to help with funding of GMP material.

We are thinking of doing a PR potentially Friday am Europe time

Would you be open to do a joint PR. NIH. CEPI and moderna sharing our partnership ? Antigen design. mRNA platform. Funding and pandemic response.

Let us know

Cheers

Stephane

Get [Outlook for iOS](#)

 **Please consider the environment before printing this email**

Confidentiality notice and disclaimer: The information in this message and any attachments is intended for the exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, of any such information by persons or entities other than the intended addressee(s) is prohibited. If you have received this message in error and are not the intended addressee, please notify the sender immediately and delete this message and any attachments from your system without reading or disclosing them. If you are not the intended addressee, be advised that any use of the information in this message and any attachment is prohibited and may be unlawful, and you must not copy this message or attachment or disclose the contents to any other person.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 20 Mar 2020 14:50:30 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD: Special ICD Meeting - Science of COVID-19
Attachments: RE: COVID-19 science brainstorm at NIH, and town meeting, Meeting on the science of COVID-19, Wed. 3/25, 2 - 5 pm, Updated agenda for COVID-19 science meeting tomorrow, FINAL Agenda Trans-NIH COVID-19 Science Meeting March 25.docx

Meeting on the science of COVID-19

Wednesday, March 25, 2020

2:00 pm | (UTC-04:00) Eastern Time (US & Canada) | 3 hrs

Meeting number (access code): (b) (6)

Meeting password: (b) (6)



Join from a video system or application

Dial (b) (6)

You can also dial (b) (6) and enter your meeting number.

Join by phone

Tap to call in from a mobile device (attendees only)

(b) (6) Call-in toll number (US/Canada)

[Global call-in numbers](#)

Join using Microsoft Lync or Microsoft Skype for Business

Dial (b) (6)

[Can't join the meeting?](#)

IMPORTANT NOTICE: Please note that this Webex service allows audio and other information sent during the session to be recorded, which may be discoverable in a legal matter. By joining this session, you automatically consent to such recordings. If you do not consent to being recorded, discuss your concerns with the host or do not join the session.

Good Morning –

Unfortunately the Monday time slot we polled for yesterday does not appear to work. Could you please respond to confirm your availability for an IC Directors WebEx Meeting on Wednesday, March 25 at 2 PM - 5 PM EDT to discuss **Trans-NIH brainstorming on COVID-19 science**.

Thanks

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 20 Mar 2020 02:53:30 +0000
To: Collins, Francis (NIH/OD) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]; Folkers, Greg (NIH/NIAID) [E]
Subject: RE: COVID-19 science brainstorm at NIH, and town meeting

Francis:

I was just told by the VP's office that I will have to be at the press conference between 11:00 and 12:30 PM. And so I definitely cannot be at NIH physically at 1:00 PM and if the press conference starts and finishes late, I may not even be able telephone in. My guess is that it will end before 1:00 PM and so I will likely be able to phone in. Let us see how tomorrow unfolds. Regarding the session of IC Directors, this would be fine with me.

Best,
Tony

Patty:

Please let us discuss the phone in logistics if I cannot physically get there.
Thanks,,
Tony

From: Collins, Francis (NIH/OD) [E] (b) (6)
Sent: Thursday, March 19, 2020 9:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Tabak, Lawrence (NIH/OD) [E] (b) (6)
Subject: COVID-19 science brainstorm at NIH, and town meeting

Hi Tony,

Nice Facebook session with Zuck! And I heard you were just on CNN, but I missed that one. I did an interview with Sheila Kaplan late this afternoon – and she greatly appreciated your message of apology. I don't think I said anything in the interview that would upset the administration.

When we spoke yesterday, you were enthusiastic about the convening of a 2 – 3 hour session of IC Directors and SMEs from their ICs, to brainstorm about additional scientific efforts that could be mounted at NIH to address COVID-19. It looks as if this can be arranged for an early afternoon next week. Obviously there would be nothing better than to have you there in person for this. While I know your schedule is not exactly under your control, is there any 2 – 3 hour period next week that might have a chance of being open for you? If not, who would you want to be the presenter of the current portfolio of NIAID investments? Hugh? Hilary? Cliff? John M? Barney? Some combination? I would want to start with a survey of that landscape (over maybe 15 minutes), and then invite ICs with ideas (some of which Hilary has already been gathering from the Deputies) to present – in the categories of basic virology/immunology, diagnostics, therapeutics, vaccines/passive immunization, and behavioral research. Do those sound like the right categories to you?

We have the NIH virtual Town Meeting at 1 PM tomorrow. Is there any chance you can come to Wilson Hall in person for that? If not, is there a chance you can call in? I will serve as moderator, and after a few minutes of opening remarks, would hope to turn this over to you for ten minutes or so of the unique Fauci perspective. After that, Larry and Alfred will talk for a few minutes about the NIH COVID Response Team, and Jim Gilman will talk about what's happening at the CC. Then we'll open it up to questions, which we can accept in real time from the estimated 20,000 staff who will be logged in. But you wouldn't need to stay for all that – if we could somehow have your participation (either in person or on the phone) from about 1:10 to 1:20, that would be really wonderful. Please let me know if that will be possible.

Sorry about the long e-mail. Get some sleep!

Best, Francis

From: Collins, Francis (NIH/OD) [E]
Sent: Mon, 23 Mar 2020 01:38:27 +0000
To: ICDDIR-L@LIST.NIH.GOV
Cc: Tabak, Lawrence (NIH/OD) [E]; Wolinetz, Carrie (NIH/OD) [E]; Anderson, James (NIH/OD) [E]; Parker, Ashley (NIH/OD) [E]; McManus, Ayanna (NIH/OD) [E]; Wood, Gretchen (NIH/OD) [E]
Subject: Meeting on the science of COVID-19, Wed. 3/25, 2 - 5 pm
Attachments: COVID-19 TransNIH Draft1_032520.docx

Colleagues,

I'm glad to hear that most of you are able to join a three-hour virtual meeting on Wednesday March 25 to discuss scientific opportunities in the effort to conquer the COVID-19 pandemic. While NIAID rightly has the lead in this effort for NIH, and is deeply invested in projects in both their intramural and extramural programs, it's clear that a number of other ICs have creative ideas and a strong motivation to try to help with this global crisis. So this certainly seems like a time where we should gather (virtually of course) to brainstorm together, led by NIAID, and seek to identify any additional areas of contribution that could be subject to acceleration and/or collaboration.

Hilary Marston recently convened a Deputies meeting on this subject, and ICs were then asked to submit examples last Friday of projects they are pursuing in the COVID-19 space. Those were forwarded from Bob Eisinger to me. I have used those submissions, including a detailed list of NIAID projects, to put together a tentative agenda for Wednesday's meeting. That is attached.

You will see that the meeting has been organized into themes (Basic Science, Natural History Studies,...). For each theme, I would ask NIAID senior staff to start off by presenting their major projects, using 1 to 4 slides as needed. Then for each IC listed, I would want to have a single slide and a two minute presentation of the idea. At the end of each theme, there should be time for discussion of the ideas presented, and reflections on what gaps are present.

There are admittedly a lot of themes and topics here, so this will require some real discipline in the one-slide presentations. I will try to serve as time-keeper – or maybe I'll ask Larry to do that. 😊

All IC Directors are invited to have one or two subject matter experts join them for this virtual discussion.

Ashley Parker (b) (6) will be helping me with the logistics and will have further instructions about how the log in will work.

Here's the specific follow up request that needs your immediate attention:

1. If your IC is pursuing a highly relevant project that's not listed here, and that you want the group to hear about, please send me that information ASAP.
2. If your IC is on the draft agenda to make a presentation, please submit your one slide (except for NIAID, who gets more) to me and Ashley by COB Tuesday 3/24. That way we can put the whole set together as a single ppt file.

Many thanks! This should provide a welcome respite from the many other tasks we are all facing right now.

Francis

From: Collins, Francis (NIH/OD) [E]
Sent: Tue, 24 Mar 2020 15:53:41 +0000
To: ICDDIR-L@LIST.NIH.GOV
Cc: Parker, Ashley (NIH/OD) [E]
Subject: Updated agenda for COVID-19 science meeting tomorrow
Attachments: DRAFT Agenda Trans-NIH COVID-19 Science Meeting March 25_032420 1140 AM.docx

Dear Colleagues,

Thanks to many of you who provided additional information to help organize the agenda for our three-hour coronavirus extravaganza tomorrow. Several of you suggested additional topics and presentations, but I regret I was only able to accommodate a few of those, given the time constraints. Hopefully those ideas can be raised in the discussion sections that will happen after each theme.

Here's what I need from you now:

- Please review the agenda to see what assignment(s) you and your IC have been given. If there is a need to change the name of the actual presenter(s), please let Ashley know ASAP. I apologize that it was not possible to include presentations from every single IC, but I tried to hit a wide range of projects.
- If you think that your assignment(s) are incorrect, please let me know right away. But sadly, I don't think we can add any more topics or presenters at this time. Keep in mind that this meeting tomorrow is not intended to be the final word on what we can do together to address COVID-19 – we will need to establish other follow up plans.
- In thinking about what to highlight in these two-minute, one-slide presentations, I would urge that you focus on a specific project that is directly relevant to COVID-19. Slides that just show bullets of a wide range of topics your IC is pursuing may not be all that useful. Please prepare for the fact that the two minute limit is going to be rigorously enforced!
- Please be sure that your one slide presentations are sent to Ashley by COB today. She will paste these all together into one master set, so that we don't run into trouble with switching screen controls.
- The final agenda and the master set of slides will be distributed tomorrow AM.

Please forgive me if this agenda does not capture all of the important and interesting things that your IC is doing. Even three hours will not be nearly enough for that!

You are welcome to invite one or two people from your IC to join the virtual meeting. Experience suggests the technology works best if the hookup for the slides is done by WebEx, but the audio is done by phone for those who are going to speak.

Looking forward to a very interesting meeting.

Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 16 Mar 2020 13:51:44 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: WH Press Conference
Attachments: ASF: press release and "cheat sheet", CONDENSED mRNA phase 1 talking points 3.14 CB.docx, FW: White House Coronavirus Press Conference Today

All –

Your principal's attendance is being requested by the Vice President for this afternoon's press conference.

Please have your principal arrive at The White House and proceed to the West Wing Lobby **no later than 2:45 pm.**

I've copied Kelly Love and Ninio Fetalvo, who will be able to answer any questions and provide more details for this afternoon's press conference.

Kelly Love: [REDACTED] (b) (6)

Ninio Fetalvo: [REDACTED] (b) (6)

From: Billet, Courtney (NIH/NIAID) [E]
Sent: Mon, 16 Mar 2020 13:07:48 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: ASF: press release and "cheat sheet"
Attachments: NIAID press release mRNA Phase 1 FINAL.docx, CONDENSED mRNA phase 1 talking points 3.14 CB.docx

Resending per Patty.

From: Billet, Courtney (NIH/NIAID) [E]
Sent: Sunday, March 15, 2020 10:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; Folkers, Greg (NIH/NIAID) [E] <(b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6)>
Subject: ASF: press release and "cheat sheet"

Attached, per discussion.